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CHAPTER I 
 
INTRODUCTION 
 
Adult T-cell leukemia/lymphoma (ATLL) is a T-cell malignancy initiated by 
infection with the human T-cell lymphotrophic virus type 1 (HTLV-1)1, 2. ATLL is a 
historically incurable disease where most patients succumb within the first year of 
diagnosis. Standard chemotherapy and monoclonal antibody treatments for ATLL 
tumor markers do not improve outcome3, 4. Development of ATLL requires HTLV-
I retroviral infection, which is followed by accumulation of somatic mutations and 
changes in gene expression. The discovery of genes and pathways involved in 
the initiation of ATLL may provide novel therapeutic targets for this fatal disease. 
So far, no drug targets have been identified. Since the IL-2 signaling pathway 
plays an important role in ATLL development, mutational analysis of IL-2 
signaling pathway components should yield a better understanding of disease 
progression and outcome. Janus kinase 3 (JAK3), a non-receptor tyrosine kinase 
that directly regulates the phosphorylation of signaling transducer and activator of 
transcription 5 (STAT5), is the most proximal kinase in the IL-2 signaling 
pathway. Activating somatic mutations in JAK3 were described in a few 
leukemias and lymphomas, including acute megakaryoblastic leukemia and 
natural killer/T-cell lymphoma5-8. Here, three mutations in the regulatory FERM 
domain of JAK3 were identified in four of the thirty-six ATLL patients are 
described. No mutations were found in twenty-three ethnically matched controls 
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screened. These somatic, missense mutations occurred in the amino terminal 
regulatory FERM domain. In cell culture assays, all three mutations induce gain 
of function in JAK3. Previous to this study, no activating mutations were 
characterized within the FERM domain of JAK3.  
Here, kinase activity is inhibited by a specific kinase inhibitor, tofacitinib, 
for WT as well as mutant JAK3s. The major function of the JAK3 FERM domain, 
as previously investigated, is to bind the cytoplasmic tail of γc (common gamma 
chain, subunit of IL-2 receptor). JAK3 FERM domain may also play an 
autoregulatory role by inhibiting kinase activity in the absence of cytokine 
stimulation. One of the JAK3 FERM domain mutations (E183G) was 
characterized in vivo and found to be oncogenic in cooperation with the loss of 
cell cycle regulator proteins p16(INK4a) and p14(ARF), both of which are 
encoded by the CDKN2A locus.  
 
Adult T-cell leukemia/lymphoma (ATLL) 
 
Description of the disease  
First described in Japan in 1976, Adult T-cell leukemia/lymphoma (ATLL) 
is an aggressive and rarely curable cancer caused by infection with the retrovirus 
Human T-cell Leukemia Virus type-1 (HTLV-1)1, 9. The virus, and the lymphoma, 
is endemic to islands in Japan and the Caribbean. Some sporadic cases were 
diagnosed elsewhere in the world including Africa, Iran, and North and South 
America10-12.  
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 ATLL is an aggressive T-cell neoplasm that is resistant to many therapeutic 
approaches. Onset of ATLL is most common during middle age or later. Upon 
diagnosis, ATLL usually runs a rapid course, with peripheral blood and bone 
marrow involvement, hepatomegaly, splenomegaly, peripheral lymph node 
enlargement, skin lesions, diffuse organ infiltration and immune suppression. 
Symptoms include lethargy, abdominal pain, diarrhea, cough, and ascites1, 13. 
Anemia, neutropenia, or thrombocytopenia rarely occur in ATLL patients, while 
pancytopenia occurs in some ATLL patients because of infiltration of leukemia 
cells into bone marrow. Aggressive ATLL has a poor prognosis because of 
resistance to chemotherapy, a high tumor burden, hypercalcemia, and profound 
immune deficiency14, 15. An elevated number of abnormal lymphocytes is 
common in acute and chronic ATLL. Neutrophilia is frequently observed in ATLL 
patients and may be caused by cytokines, such as granulocyte/macrophage 
colony-stimulating factor, produced by ATLL cells16. 
Because the disease is rare, mostly small case studies of 1-12 patients 
have been published. These studies have looked at cytotoxic chemotherapy, 
interferon therapy, nucleoside analogues, stem cell transplantation, and immune 
therapy, but no specific regimen has generated reproducible results17, 18. ATLL is 
resistant to both chemotherapy and targeted immunotherapy and these 
treatments do not alter the clinical course of the disease4, 18, 19. Historically, most 
patients succumb within the first year of diagnosis. Longer survival of greater 
than two years is rarely observed in patients presenting with chronic or 
smoldering forms of ATLL20-23. Less than 10% of the patients survive up to five 
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years after the initial diagnosis. 
Cases of increased survival have been reported after stem cell 
transplantation but the treatment-related mortality is still extremely high24. 
Unfortunately, newly diagnosed patients can expect a median survival of less 
than 12 months. Perhaps through better understanding of the unique biology of 
ATLL, it may be possible to identify novel therapeutic targets.  
It was observed that patients with acute ATLL benefit considerably from 
combined antiviral therapy with zidovudine and interferon alpha, whereas 
patients with ATLL of the lymphoma type may experience a better outcome with 
intensive chemotherapy25. Up to 40% of patients treated with stem-cell 
transplantation achieved remission for 12-18 months26.  
 Very few cases of remission have been described for aggressive ATLL27, 28. 
For instance in one case study 35 patients were treated with conventional 
chemotherapy, followed by allogeneic hematopoietic stem cell transplantation, 29 
of these patients were subsequently treated by the withdrawal of immune 
suppressants. Of these 29, only 2 patients were in remission at 48 and 69 
months post relapse or progression at the time of publication28. A large scale 
meta-analysis of ATLL clinical case studies between 1995 and 2008 compared 
with patient outcomes for 100 patients with ATLL found that patients with ATLL 
experienced a better outcome with chemotherapy and without antiviral therapy29.  
HTLV-1 infects T cells and induces cell transformation through the 
expression of viral oncogenes such as tax30-32. ATLL cells are identified as 
activated helper T-cells with a CD3+, CD4+, CD8−, CD25+, and HLA-DR+ surface 
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phenotype. In some rare cases, ATLL cells express both CD4 and CD8 on their 
surfaces and, very rarely, CD8 alone or lacking in both CD4 and CD8 
expression33-35. Histological/morphological characteristics of ATLL leukemic cells 
include lobular nuclei and unusual surface phenotypes1. 
 
Human T-cell lymphotropic virus type 1 (HTLV-1) 
Ten and twenty million people worldwide are estimated to be infected with 
the HTLV-I, but only 10%, are estimated to become chronic viral carriers of 
infection11, 18, 36-39. It should be noted that these estimates are usually based on 
screenings of blood donors, pregnant women and select at risk population. 
These methods may lead to an inaccurate estimation of the prevalence of 
infection37. The highest prevalence is reported in the Japanese islands of 
Okinawa and Tsushima and theoercent of the poputlaiton that is infected was 
estimated at between 17.1% and 36.4% in the 1980s and 1990s40. 3.8% of 
Haitians are carriers of HTLV-1 as of 199337. In African studies, the prevalence is 
between 1.05% and 8.5%41-43. HTLV-1 is higher in females and increases with 
age42, 44, 45. HTLV-1 prevalence is known to vary widely over geographic and 
demographic populations, therefore the exact prevalence is unknown37, 46, 47. 
Viral transmission occurs by sexual contact, from mother to child via 
breastfeeding, and through exposure to contaminated blood, either through blood 
transfusion or sharing of tainted needles48-50. Co-infection with HTLV-I and HIV 
can accelerate the progression of acquired immune deficiency syndrome 
possibly due Tax activation of the HIV LTR51-54. Several receptors have been 
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suggested as integral to HTLV-1 infection including the glucose transporter 
receptor-1, neuropilin-1, and heparan sulfate proteoglycans55-62.  
Formerly referred to as Adult T-cell lymphoma virus type 1, HTLV-I was 
first identified in the cell line MT-2 derived from coculture of cord blood with cells 
isolated from an ATLL tumor2. HTLV-1 was the first human retrovirus to be 
identified and is the only known retrovirus directly linked to a human cancer. 
Although the majority of infected individuals remain asymptomatic throughout life, 
HTLV-1 infection is linked to life-threatening, incurable diseases, such as HTLV-I 
associated myelopathy/tropical spastic paraparesis (HAM/TSP) and ATLL in 5-
10% of carriers 20-50 years after infection2.  
 HTLV-I is a member of the primate T lymphotropic viruses family. Members 
include human T-cell leukemia/lymphotropic viruses HTLV-I, HTLV-II, HTLV-III 
and HTLV-IV and viruses that infect old-world primates such as Simian T-
lymphotropic viruses STLV-I, STLV-II, STLV-III, and STLV-V63-66. HTLV-I is an 
enveloped, diploid single-stranded RNA virus of the Retroviridae family. Upon 
infection, the genome is copied into a double-stranded DNA form that integrates 
into the host cell genome, and at this point the virus is referred to as a provirus67. 
HTLV-1 is a complex retrovirus that specifically targets CD4 positive T cells for 
infection. Oligoclonal expansion of HTLV-I-infected cells in vivo is also observed 
in HAM/TSP patients and some asymptomatic HTLV-I carriers, showing that 
HTLV-I-infected cells have proliferative potential68. 
 The HTLV-1 provirus contains multiple gene products that contribute to T-
cell transformation. One of these genes is the retroviral oncogene tax. Tax 
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expression was shown to induce T-cell immortalization on its own69. In newly 
infected cells, Tax activates the expression of the cytokine Interleukin-2 (IL-2) 
and the alpha subunit of its receptor (IL2RA), resulting in autocrine signaling that 
drives cell proliferation. In patients, full transformation into ATLL involves a long 
latency of up to five decades. Transformation by the virus both in vitro and in 
patients occurs in a slow stepwise manner and progresses from a polyclonal to a 
monoclonal dominant clone with respect to proviral integration and decreased 
dependence on IL-2 for proliferation68, 70-73. Conversely, the level of HTLV-I 
antigen expression in freshly isolated peripheral ATLL cells is extremely low. 
Human T-cell leukemia virus type I core, envelope, polymerase and Tax proteins 
are recognized by HTLV-I-specific cytotoxic T-lymphocytes74-76. Tax is frequently 
deleted or epigenetically silenced by deletion or promoter methylation 
respectively, within the proviral allele; however, there is constitutive activation of 
proteins downstream of IL-2 induction77, 78. The loss of tax could be induced by 
an immune response against Tax expressing T cells79-81. 
Because the ATLL cells maintain high levels of proliferation and signaling 
downstream of IL-2 despite the loss of tax expression82-84, this population of cells 
is at risk for the development of genetic and cytogenetic changes leading to 
lymphoma. These high levels of proliferation suggest that gain of function 
mutations must occur within this pathway in host cells. Activating mutations in the 
kinase necessary to this pathway may play a role in transformation. Somatic gain 
of function mutations in the IL-2 pathway would explain the long latency before 
disease manifestation and the extremely low penetrance of the disease.  
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Once the IL2Rα chain expression is up-regulated by Tax, the high affinity 
heterotrimer of the IL-2 receptor is formed. JAK3 is constitutively bound to the 
common γ chain of the IL-2 receptor where it phosphorylates its targets85, 86. 
Upon ligand binding, the non-receptor tyrosine kinases, JAK1 and JAK3 are 
activated; this initiates phosphorylation of important downstream substrates 
including signal transducer and activator of transcription 5 (STAT5). Other 
downstream targets such as AKT (Protein Kinase B) are important for T cell 
survival87. Although the viral oncoprotein Tax was shown to play a significant role 
in leukemogeneis, when most of the HTLV-I infected cells no longer express Tax, 
tax repression is important for the early carrier phase88. Additional cellular 
mutations must be acquired for the development of ATLL. 
 
Interleukin Signaling and the JAK/STAT Pathway 
 
Interleukin Receptor Family 
Cytokines function by binding the extracellular portions of receptors, 
leading to the phosphorylation and activation of the receptor and proteins to the 
intracellular portion of the receptor. Once triggered by specific cytokines, the 
JAK/STAT pathway influences immune response, embryonic development, and 
cellular transformation. Most cytokine receptors lack intrinsic kinase activity but 
instead interact with the Janus kinase family of non-receptor tyrosine kinases. 
The activity of the JAKs directly induces downstream responses.  
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Interleukin 2 (IL-2) Receptor Signaling 
Interleukin-2 (IL-2) was discovered in 1976 as a T-cell growth factor-
exhibiting activity in the supernatants of activated T cells89. IL-2 is produced 
primarily by CD4+ T cells following their activation by antigen. IL-2 is a cytokine 
that drives multiple aspects of T-cell growth, augments natural killer cell (NK) 
cytolytic activity, and induces the differentiation of regulatory T cells. The 
heterotrimeric IL-2 receptor is composed of α, β, and γ chains. The β and γ 
chains are constitutively expressed in T cells. Three different IL-2 receptor chains 
exist that together generate low, intermediate, and high affinity IL-2 receptors90, 91 
(Figure 1). The ligand-specific IL-2 receptor α chain (IL-2Rα,CD25, Tac antigen), 
which is expressed on activated but not non-activated lymphocytes, binds IL-2 
with low affinity. The combination of IL2Rβ (CD122) and IL2Rγ (common 
cytokine receptor γ chain (γc) or CD132) together forms an IL-2Rβ/γc complex in 
memory T cells and NK cells that binds IL-2 with intermediate affinity. When all 
three receptor chains are co-expressed on activated T cells and regulatory T 
cells, IL-2 is bound with high affinity (Figure 1)92. IL-2 induces heterodimerization 
of IL-2Rβ and γc chains of its receptor and activates the Janus family tyrosine 
kinases, Jak1 and Jak3. Whereas Jak1 associates with IL-2Rβ, Jak3 associates 
primarily with γc but also with IL-2Rβ. Jak3-IL-2Rβ association is  
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Figure 1. The heterotrimeric IL-2 receptor. IL2R is comprised of α, β, and γ 
subunits. JAK3 protein (grey) binds the γ subunit via the FERM domain (F). Upon 
stimulation with IL-2, JAK3 is activated and phosphorylates STAT5.  
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Jak1-independent, this association is important for IL-2-induced Stat5 activation. 
Jak1 and Jak3 were shown to associate only in the presence of IL-2Rβ, 
demonstrating that these kinases can not directly converge but instead 
simultaneously bind to IL-2Rβ93, 94.  
The IL-2 signal leads to the activation of three major signaling pathways: 
phosphoinositol-3’-kinase (PI3K)/AKT, Ras-MAP kinase, and JAK-STAT 
pathways, with JAK1 and JAK3, and STAT5A and STAT5B being the JAKs and 
STATs involved. Simultaneous loss of both Stat5a and Stat5b leads to perinatal 
lethality with anemia and leukopenia. Together, these three signaling pathways 
mediate cell growth, survival, activation-induced cell death, and differentiation92, 
95. 
 
Janus Kinases (JAKs) 
 
Janus Kinase Receptor Family 
While JAK1, JAK2 and TYK2 are expressed ubiquitously, JAK3 is thought 
to be specifically expressed in hematopoietic cells including B-cells, T-cells and 
natural killer cells96-98. The moniker refers to the two-faced Roman god, Janus, 
because the JAKs possess two near-identical phosphate-transferring domains, 
the kinase and pseudokinase domains. One domain exhibits the kinase activity, 
while the pseudokinase domain negatively regulates the activity of the first99-101.  
The JAK proteins are comprised of FERM, SH2, pseudokinase and kinase 
domains102. The FERM domain is predominantly responsible for binding the 
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cytoplasmic tails of cytokine receptor chains103, 104. The pseudokinase domain 
structurally resembles a kinase domain but does not function as one and acts as 
a negative regulator of kinase activity99. 
Crystal structures for all four family members have been illustrated for the 
C-terminal kinase domains in the presence of ATP binding site occluding 
inhibitors including tofacitinib105-109. No other domains have been crystallized for 
any of the Janus kinases. Janus kinases are critical to the signaling induced by 
various interleukins. They are therefore involved in regulation of the immune 
system and were found to play crucial roles in the development of various 
diseases including cancer and autoimmune disorders that are associated with 
dysregulation of these signaling pathways. Since many cytokine receptor 
proteins lack enzymatic activity, they are dependent upon JAKs to initiate 
signaling upon binding of their ligands.  
JAK activation results in phosphorylation of the STAT transcription factors. 
There are seven known members of the STAT family of transcription factors: 
STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. Upon activation 
of the receptor, the relevant JAK family member is phosphorylated, allowing it to 
interact with and subsequently phosphorylate a specific STAT. Upon activation, 
STAT complexes translocate into the nucleus, bind DNA, and initiate 
transcription110.  
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Janus Kinase 3 (JAK3) 
Janus kinase 3 (JAK3) is a non-receptor tyrosine kinase vital to the 
regulation of B and T-cells. JAK3 has four characterized domains: the kinase 
domain, the pseudokinase domain, the SH2-like domain and the FERM domain. 
The kinase domain is the principal domain for JAK3 activity. The pseudokinase 
domain was shown to be involved in regulating the activity of the kinase 
domain111. JAK3 is required for signaling of the type I receptors that use the 
common γc chain. JAK3 constitutively binds the cytoplasmic tail of γc via the 
JAK3 FERM domain. Upon binding of cytokine, the receptor allosterically 
changes, triggering the bound JAKs to autophosphorylate and to phosphorylate 
the receptor itself at specific tyrosines. 
Mutations that abrogate JAK3 function cause autosomal severe combined 
immunodeficiency disorder (SCID). JAK3 knockout mice do not possess T-cells 
and have a reduced number of nonfunctioning B-cells112. JAK3 is a mediator of 
interleukin-8 (IL-8) stimulation of neutrophils in addition to its well-known roles in 
T cells and NK cells113. 
 
FERM Domain  
The FERM domain is named for the four proteins it was originally 
identified in, band 4.1, ezrin, radixin, and moesin. FERM domains are present in 
structural proteins such as the ezrin-radixin-moesin (ERM) family of proteins as 
well as in signaling proteins such as FAK and several tyrosine phosphatases114. 
Two different mechanisms for regulation of protein interactions by FERM 
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domains have been described. In the first mechanism, FERM domains can 
mediate intermolecular interactions, usually at the site of direct interaction with 
the cytoplasmic tails of transmembrane proteins115. In the second mechanism, 
FERM domains can function to directly regulate protein function for the core 
protein via intramolecular interactions. The best-characterized FERM domain-
mediated interactions are those of the ERM family of proteins. The ERM proteins 
bind via their FERM domains to the cytoplasmic domains of transmembrane 
proteins such as CD44116. Other examples of FERM domain-mediated 
intermolecular interactions include binding of the FERM domains of JAKs with 
the γc and gp130 subunits of cytokine receptors. The FERM domains of the ERM 
proteins also bind intramolecularly to a site within the C terminus. This interaction 
obscures the CD44 binding site within the FERM domain and an actin-binding 
site in the C-terminal tail. The major function of the JAK3 FERM domain was 
described as binding the cytoplasmic tail of γc117. The FERM domain of JAK3 
interacts with the C-terminal catalytic domain, and this interaction was shown to 
mediate catalytic activity111. When coexpressed, the FERM domain directly 
associated with and enhanced the activity of the isolated kinase domain in 
JAK3111. 
 FERM domains are made up of three subdomains: F1 with a ubiquitin-like-
grasp fold, F2 with an acyl-coenzyme A-binding protein like fold, and F3 which 
shares the fold of phosphotyrosine binding. F1, F2, and F3 together form a 
compact clover-shaped structure118-120.  
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The role of Janus kinases in disease 
Janus kinases are critical to the development and function of multiple 
hematopoietic lineages. Loss of Jak1, Jak3, or Tyk2 results in impaired 
lymphopoiesis whereas Jak2 deficiency results in embryonic lethality because of 
the absence of definitive erythropoiesis. These effects are attributed to lack of 
signaling through various cytokine induced pathways121-129.  
The JAK family kinases are central players in normal and malignant 
hematopoiesis and are potentially subject to oncogenic somatic mutations. These 
non-receptor tyrosine kinases are recruited for signal transduction by cytokine 
receptors that do not possess tyrosine kinase activity of their own102. Genetic 
activating or gain-of-function mutations predominantly located within the 
pseudokinase domains of Janus kinase family members have been associated 
with to the development of various hematologic malignancies.  Mutations in JAK1 
and JAK3 have been associated with acute myeloid leukemia, acute 
lymphoblastic leukemias, T cell acute lymphoblastic leukemia and natural killer/T-
cell lymphoma5, 6, 130-135 138, 146. JAK2 mutations have been described in B lineage 
acute lymphoblastic leukemia, myeloid malignancies, and myeloproliferative 
neoplasms133, 136-140. One of the most studied Janus kinase mutations occurs in 
the pseudokinase domain of the JAK2, V617F141. The discovery of this mutation 
led to studies on drug treatments, led to advancements in understanding of the 
pathogenesis of disease, allowed for revisions in classification and diagnostic 
criteria, and provided a target for treatment of myeloproliferative neoplasms 
(MPNs). As valine 617 of JAK2 is conserved as valine 678 of TYK2, the effect of 
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a homologous mutation in TYK2 V678F also has the potential to induce disease. 
TYK2 V678F augments the transcriptional activity of STAT3 and STAT5 and 
induces BaF3 autonomous cell growth and hyper-responsive to IL-3142. This 
mutation is not derived from an existing tumor. Mutations in TYK2 have been 
implicated in multiple sclerosis, autoimmune disease, and systemic lupus 
erythematosus143-145.  
In addition to this work on ATLL, JAK3 mutations have also been 
implicated in the development of acute megakaryocytic leukemia and natural 
killer T cell lymphoma.  It is important to note that the only other mutation 
described in the FERM domains for any members of this family is a rare non-
synonymous single nucleotide polymorphism (SNP) P132T that has been 
implicated in acute megakaryocytic leukemia5, 6.  
IL2RG is mutated in humans with X-linked severe combined 
immunodeficiency (XSCID) and physically interacts with JAK3, which when 
mutated also causes a T-B+NK− form of SCID117, 147-149. In XSCID and JAK3-
deficient SCID, the lack of signaling by IL-7 and IL-15, respectively, explains the 
lack of T and NK cell development150, whereas defective signaling by IL-4 and IL-
21 together explain the non-functional B cells found in this disease151. Some of 
these germline SCID mutations occur in the FERM domain of JAK3 and abolish 
binding to γc, while others create a premature stop codon, which generates a 
truncated kinase negative form of JAK3149, 152. JAK3 deficient mice express a 
similar phenotype with a complete loss of T and NK cell development and non-
functioning B cells.  
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Cell Cycle Regulators ARF/INK4A 
 
Tumor suppression and cell cycle regulation 
The CDKN2A locus encodes two tumor suppressor genes, p16(INK4A) 
and p14(ARF) in human or p19(ARF) mouse, transcribed using alternative exons 
1 (alpha) spliced onto the same exons 2 and 3153. p16(INK4A) and p14(ARF) are 
crucial for two cancer suppressor pathways and are both capable of inhibiting 
cell-cycle progression. p14(ARF) functions as an indirect stabilizer of p53, and 
p16(INK4A) inhibits cyclin-dependent kinase 4. 
 
Role of CDKN2A family in leukemia 
The homozygous deletion of CDKN2A was detected at high rates in many types 
of leukemias154-159. Alterations of CDKN2A expression occur in 17-68% of the 
acute and 5-26% of the chronic ATLL samples160-166. CDKN2A deletions were 
associated with the development of acute/lymphomas but not chronic/smoldering 
ATLL suggesting that these genetic events drive the late stage of 
leukemogenesis in ATLL. In chronic myelogenous leukemia, alteration of 
CDKN2A is involved in the progression to lymphoid blastic crisis from the chronic 
phase as well as the evolution from low grade to high grade Non-Hodgkin 
lymphoma167, 168. Similarly, there is a higher frequency of deletions of CDKN2A 
in acute lymphoblastic leukemia (ALL).  
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Loss of CDKN2A expression leads to a pathologically higher grade 
malignant behavior, progressive disease, and poor outcome. ATLL patients with 
a deleted CDKN2A have a significantly shorter survival rate than those with an 
intact gene169. Acute ATLL individuals with deletions of CDKN2A survived for 
less than three years, whereas ATLL patients with the gene intact survived for up 
to eight years161.  
Methylation of the 5' CpG island of CDKN2A is associated with 
transcriptional silencing of this gene in many neoplasms, including leukemias and 
lymphomas170-172. The CDKN2A is more frequently methylated in fresh tumor 
cells isolated from patients with acute (47%) and lymphomatous (73%) than in 
those with chronic (17%) and smoldering (17%) ATLL. The expression of p16 
mRNA was markedly decreased in the samples with methylated CDKN2A, 
especially if the p16 promoter region was methylated. In contrast, methylation of 
p16 was not identified in asymptomatic HTLV-1 carrier or uninfected 
individuals173. Tax-immortalized T cell lines and normal CD4+ T cells expressed 
comparable levels of p16 mRNA174.  
Tax suppresses p16-mediated inhibition of U2OS cell growth and directly 
interacts with p16(INK4A)175, 176. A point mutation of p16 is present in the HTLV-I 
infected MT-1 cells, and these cells do not express TAX. In contrast, wild-type 
p16(INK4A) is abundantly expressed in MT-2 and Hut-102 cells and they do 
express TAX. These results suggest that inactivation of p16(INK4A) expression 
either by genetic alteration or possibly TAX expression is important for T cell 
transformation169.  
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Table 1. Origins of Ethnically matched control samples.  
 
Samples # Specimen ID Country of Origin 
1 V280 Haiti 
2 V289 Haiti 
3 V290 Jamaica 
4 V291 Haiti 
5 V292 Haiti 
6 V293 Jamaica 
7 V295 Jamaica 
8 V281 Jamaica 
9 V296 Haiti 
10 V297 Jamaica 
11 V298 Haiti 
12 V299 Haiti 
13 V304 Haiti 
14 V307 Haiti 
15 V312 Jamaica 
16 V314 Jamaica 
17 V318 Haiti 
18 V319 Jamaica 
19 V321 Jamaica 
20 V322 Jamaica 
21 V325 Jamaica 
22 V326 Jamaica 
23 V327 Jamaica 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Patient samples, sequencing, and mutational analysis 
Genomic DNA was isolated from 36 ATLL patients, who were treated at 
the NIH Clinical Center and consented under an IRB-approved protocol. Most of 
these patients were from Jamaica. Likewise, 23 ethnically matched control 
patients (Table 1) had whole blood drawn for genomic DNA preparation under an 
IRB-approved protocol. The entire JAK3 gene was analyzed by PCR 
amplification of specific exons (Table 2) and analyzed for sequence alterations 
by SpectruMedix's Reveal Genetic Analysis System on samples where the 
leukemia cells were purified from the buffy coat. Standard Sanger DNA 
sequencing (GeneWiz and Vanderbilt Core Sequencing facility) was 
subsequently used to analyze all potential mutations as determined by Reveal 
Genetic Analysis System. Multiple independent PCR amplicons cloned into 
pGEM-T Easy (Promega) were used to analyze samples that did not have pure 
leukemic samples or in some instances had <10% leukemic cells. 
Oligonucleotide primers used for PCR are available in Table 3. The proposed 
JAK3 FERM domain structure was determined by ClustalW alignment with the 
FAK FERM domain and analyzed with PyMol using FAK FERM coordinates. The 
crystal structure of the JAK3 kinase domain was available from the RCSB Protein 
Data Bank107. 
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Table 2. JAK3 FERM domain mutations and SNPs identified in ATLL patients.  Three DNA 
point mutations and 1 SNP were identified in JAK3 exon 4 in five out of the thirty-six ATLL 
patients sampled.  One nonsynonymous SNP listed in the NCBI Entrez database P132T was 
identified in 1 of our 36 ATLL patients sampled.  Five Single Nucleotide Polymorphysims 
(SNPs) are listed for JAK3 FERM domain in NCBI Entrez database. 
 
Cluster id Region of JAK3 # Patients 
dbSNP 
Allele Protein Residue 
rs3212711 Intron 1 2 +HUT102 C to T NA 
rs3212712 Intron 1 2 +HUT102 G to A NA 
rs3212713 Intron 1 2 +HUT102 G to A NA 
rs3212716 Exon 3 1 C356G Leu99 synonymous 
rs3212718 Intron 3 1 A to G NA 
rs3212719 Intron 3 1 A to G NA 
rs3212723 Exon 4 1 C453A Pro132Thr 
novel mutation Exon 4 1 T525C Leu156Pro 
novel mutation Exon 4 2 A606G Glu183Gly  
novel mutation Exon 4 1 G573A Arg172Gln  
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Viruses and plasmid constructs  
MSCV-ires-GFP (MIG) constructs expressing mutant JAK3 cDNAs were 
constructed by introducing mutations into the wild type JAK3 using Stratagene 
QuikChange kit (Table 4). The wild type JAK3 and A572V JAK3 mutant 
constructs were provided by Dr. Brian Druker and cloned into MIG. Site directed 
mutagenesis was verified by full sequencing of the JAK3 cDNA insert. Virus was 
made by transient transfections of JAK3-MIG constructs into Phoenix cells by the 
CaPO4 method along with pCL-Eco. Viral titers were determined by flow 
cytometric analysis of 3T3 cellsinfected with recombinant retrovirus for GFP 
expression. pCMVSport6-IL2Rβ and pCMVSport6-STAT5A constructs were 
obtained from the Mammalian Gene Collection. IL2Rα was cloned into pcDNA 
3.1(+) (Invitrogen) from pINCY-IL2Rα (Open Biosystems) construct. IL-2Rγ was 
amplified from HuT-102 cDNA and cloned into pcDNA 3.1(+). All inserts were 
fully sequenced. 
 
 Polymerase chain reactions (PCR) 
Immunoglobulin Heavy chain  
 PCR analysis of Immunoglobulin Heavy chain (IgH) gene rearrangements 
and B cell differentiation was used to determine tumor clonality. Genomic DNA 
samples from splenic tumors were subjected to PCR with primers designed to 
amplify junctions between D and J regions. For nested PCR analysis of DJ 
recombination, genomic DNAs were subjected to PCR with primers designed to  
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amplify four possible junctions between D-Q52 and JH regions. The primers for 
the first round were: CACAGAGAATTCTCCATAGTTGATAGCTCAG (p1569, DH 
Q52-1; sense) and AGGCTCTGAGATCCCTAGACAG (p1570, JH 4-1; 
antisense). PCR conditions were as follows: denaturation at 95°C for 1 min, 
annealing at 60°C for 1 min, extension at 72°C for 2.5 min (28 cycles). Two µl 
from each reaction were subjected to a second round of PCR using a pair of 
internal primers: GCCTCAGAATTCCTGTGGTCTCTGACTGGT (p1571, DH 
Q52-2; sense) and GGGTCTAGACTCTCAGCCG-GCTCCCTCAGGG (p1572, 
JH 4-2; antisense) PCR conditions were as follows: denaturation at 95°C for 20 
s, annealing at 60°C for 1 min, extension at 72°C for 2 min (35 cycles). 
Secondary PCR products were analyzed on a 2% agarose gel177. 
 
T- cell Receptor J-beta (TCRβ)  
 PCR analysis of gene T- cell Receptor J-beta (TCRβ) rearrangements were 
used to analyze tumor clonality. Genomic DNAs from splenic tumors were 
subjected to PCR with primers designed to specifically amplify the J-beta region 
of T-cell receptor gene, TGGTTTCTTCCAGCCCTCAAG (p1242) and  
TGGAAAGAGTGGAGATGAGGCTAAGAGAAA (p1243). PCR conditions were 
as follows: denaturation at 94°C for 2 min (1 cycle), 94°C for 30 sec annealing at 
55°C for 1 min, extension at 72°C for 30 sec (30 cycles), final extension 72°C for 
7 min (1 cycles) and 4°C hold178.  
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Splinkerette (Splk) 
Nested splinkerette PCR for identifying MSCV integration sites was 
adapted from Yang Du and Neal Copeland.  One µg of genomic DNA from 
splenic tumors digested with NlaIII or MseI and SacI was  ligated to double 
stranded restriction enzyme specific  linker  Splink-NlaIII (U250, splinkerette-LN 
CCTCCACTACGACTCACTGAAGGGCAAGCAGTCCTAACAACCATG and 
U252, Splink-NlaIII GTTGTTAGGACTGCTTGGAGGGGAAATCAATCCCCT) or 
Splink-MseI (U251, Splinkerette-LM 
CCTCCACTACGACTCACTGAAGGGCAAGCAGTCCTAACAAC and U253, 
Splink-MseI TAGTTGTTAGGACTGCTTGGAGGGGAAATTCAATCCCCT). 
Primary PCR primers were (U256, MSCV-LTR1) 
TCTCGCTTCTGTTCGCGCGCTTC and (U254 Splinkerette-P1) 
CCTCCACTACGACTCACTGAAGGGC2’ and conditions were 94°C; 10 cycles 
10” 94°C, 2’ 70°C (-0.5° per cycle); 20 cycles 10” 94°C, 2’ 65°C; final extension 7’ 
70°C. Secondary PCR utilized 1:50 dilution of Primary PCR product. Secondary 
PCR primers were (U257, MSCV-LTR3) CGTCGCCCGGGTACCCGTATTC and 
(U255 Splinkerette-P2) GGGCAAGCAGTCCTAACAAC. Secondary PCR 
conditions are 2’ at 94°C; 30 cycles 15” 94°C, 30” 61°C, 1’30” 65°C; final 
extension 7’ 68°C. Final PCR products were resolved on 2% agarose gel. Bands 
were cloned using pGEM-T Easy cloning vector and sequenced.  
 
Real-time quantitative PCR  
 Genomic DNA for patient exhibiting L156P mutation was quantified for tax 
copies using quantitative PCR (qPCR). Tax quantification approximates the 
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frequency of leukemic cells in the buffy coat sample. 100 ng of total genomic 
DNA was used for PCR using the iQ SYBER Green Supermix (Bio-Rad) on an 
iCycler (Bio-Rad). PCR reactions were performed in triplicate. The expression of 
the gene of interest was calculated relative to the levels of STS.  
 
Flow cytometry and protein analysis 
Flow Cytometry Analysis  
 To obtain single cell suspensions of bone marrow, the tibias and femurs 
from each transplanted mouse were flushed. The spleens or thymi were 
pulverized to obtain single cell suspensions of transplanted mice. Peripheral 
blood was obtained by retro-orbital bleed under isoflurane-induced anesthesia. 
Red blood cells were lysed using 1ml of Erythrocyte lysis buffer for up to 2x107 
cells on ice for 5 minute. Following lysis 2x105 to 5x105 cells were aliquoted into 
individual tubes. The cells were stained with antibodies against: CD3, CD25, 
CD4, CD8, CD45.1, CD45.2, B220, CD19, Gr-1, or Mac-1.  
Flow cytometry experiments were performed in the Vanderbilt Flow 
Cytometry Shared Resource core. Flow cytometry data acquisition was 
performed on an LSRII 3 laser (BD Biosciences) and analyzed with FACS Diva 
software (BD Biosciences). BaF3 cells transduced with various MIG-JAK3s were 
sorted for GFP on a FACS Aria (BD Biosciences). These cells were also stained 
with Vybrant Dyecycle violet (Invitrogen) and the proportion of cells in each cell 
cycle stage was determined by flow cytometry and analyzed using FlowJo 
software (Tree Star).  
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Western Blot Analysis 
Immunoprecipitations were performed in BaF3 cells transduced with MIG-
JAK3 using anti-JAK3 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and 
anti-γc antibodies (R&D Biosystems, Minneapolis, MN). Detection of total and 
phosphorylated protein targets was performed using the LI-COR Odyssey® 
Infrared Imaging System. Antibodies used were anti-P-STAT5 (Y694) (BD 
Transduction Laboratories, BD Pharmingen, San Diego, CA), anti-P-AKT (S473), 
anti-ERK1/2, anti-P-ERK1/2 (T202/T204) (Cell Signaling Technology, Beverly, 
MA), anti-STAT5, anti-IL2Rα, anti-IL2Rβ, anti-γc, anti-JAK3, anti-STAT3, anti-P-
STAT3 (Y705), and anti-P-JAK3 (Y980) (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) and 680nm and 800nm infrared dye-conjugated secondary antibodies 
(LI-COR).  
 
Immunofluorescence staining  
 1x105 BaF3 cells were cytospun onto glass slides at 800rpm for 5 min, fixed 
in 3% paraformaldehyde for 15 minutes at room temperature, washed thrice with 
PBS, permeabilized in 0.5% Triton X-100 for 15 minutes at 24°C, and blocked 
with 1% fetal bovine serum (FBS) in PBS for 30 minutes at room temperature. 
JAK3 was detected using a 1:50 dilution of anti-JAK3 (Santa Cruz, sc-513) in 
10% FBS for 1 hour at room temperature, washed thrice with PBS and incubated 
with a 1:500 dilution of secondary fluorescent antibody (invitrogen 546 anti 
Rabbit IgG #A11010) and the nuclei were counterstained with 1µg/ml 4,6- 
diamidino-2-phenylindole (DAPI). Images were digitally captured using a Zeiss 
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LSM 510 META inverted confocal microscope.  
 
 Cell Culture  
HEK 293T cells 
HEK 293T and Phoenix cell lines were obtained through ATCC. 
Reconstitution of IL-2 receptor, JAK3/STAT5 pathway was performed by CaPO4 
transient transfection of 2.5 µg of pCMVSport6-STAT5a, pcDNA-3.1-IL2Rα, and 
pCMVSport6-IL2Rβ; 5µg of pcDNA3.1-γc and MIG-JAK3 constructs and grown in 
the presence of hIL-2 for 24 hours. Expression levels of all components were 
quantified by western blot or flow cytometry.  
 
BaF3 cell lines and assays 
BaF3 cells were obtained from Dr. Elizabeth Yang. Ba/F3 cells are IL-3-
dependent mouse pro-B cells and were cultured in IMDM medium supplemented 
with 10% fetal bovine serum, 1% pen/strep, and 2% supernatant of the WEHI-3B 
cell line as a source of IL-3. BaF3 cells were serially transduced 3 times and 
GFP-positive cells were sorted by flow cytometry after 6 days in culture. 
Cytokine-independent growth assays were performed as described179. Once 
cytokine independence was established, mutant JAK3 expressing cells were 
maintained in the absence of mIL-3 and used in all subsequent experiments. 
Protein stability was determined by starving BaF3 cells of serum for 1 hour 
followed by the addition of 100µg/ml cycloheximide for 0, 0.5, 1, 2, and 3 hours 
before cells were lysed and JAK3 expression analyzed by western blot analysis.  
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 Stably transduced BaF3 cells were incubated at 37 °C for 30 minutes, 1, 2, 
3, or 4 hours with proteasome inhibitors MG132 (10µM) (Sigma) or DMSO only. 
Cells were then lysed in radio-immunoprecipitation assay buffer (RIPA) with 
protease inhibitors and analyzed by western blot with antibodies against JAK3 
and tubulin. Protein expression levels were quantified and graphed180, 181.  
 Stably transduced BaF3 cells were incubated at 37 °C for 1, 4, 24, or 48 
hours with lysosome inhibitors chloroquine (0-200µM)(Sigma). Cells were then 
lysed in RIPA with protease inhibitors and analyzed by western blot with 
antibodies against JAK3 and tubulin182-185. 
The JAK3 inhibition assays were performed on BaF3 cells expressing 
mutant JAK3s using tofacitinib (Selleck Chemicals LLC, Houston, Texas) at the 
concentrations listed after zero, 12, and 24 hours. Cells were incubated with anti-
Annexin V antibody and propidium iodide and analyzed by flow cytometry at 24 
and 48 hour of incubation with tofacitinib. Protein was obtained at all time points 
and cells were counted at 0 and 24 hours. Inhibitors BEZ-235 (Selleck), BKM-
120 (Active biochem), and CI-1040 (gift of Dr. Carlos L. Arteaga) against 
PI3K/mTOR, PI3K and MEK respectively were used in (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assays as described. For MTT assays, MIG-
JAK3-transduced BaF3 cells were plated at 200,000 cells/well in a 96 well plate 
with the concentrations of 1000 cells/µl in triplicate using media without phenol 
red at concentrations of tofacitinib listed. At 48 hours 150µL of media was 
removed, 20µl of 5mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) reagent was added and cells were incubated for an additional 4.5 
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hours. Cells were lysed with the addition of 100µl 0.1N HCl in isopropanol. Plates 
were scanned on a Molecular Devices Versa Max microplate reader and data 
were analyzed using SoftMax Pro software. 
 
OP9 in vitro T cell differentiation assay 
OP9-DL1 and OP9-GFP cell lines were provided by Dr. Juan Carlos 
Zúñiga-Pflücker. The T-cell differentiation assay was performed using JAK3KO 
fetal liver cell. JAK3KO fetal liver stem cells from day E15.5 fetal livers were 
collected. JAK3KO mice were acquired from Jackson Laboratory128, 129, 186. 
Mononuclear cells were isolated using lymphocyte separation medium 
(MediaTech). Cells were magnetically sorted to enrich for c-Kit+ Lin- Sca-1+ (KLS) 
cells (StemCell Technologies, Inc., cat# 19756). KLS cells were enriched for 
using StemCell Technologies’ mouse CD117 selection cocktail (cat# 18757) and 
the correct immunophenotype was verified by flow cytometry. Cells defined by 
the KLS phenotype were then transduced with MIG-JAK3, and co-cultured with 
irradiated OP9-DL1 or OP9-GFP cells in the presence of 6ng/ml mIL-7 and 
6ng/ml mFlt3 for 28 days at a concentration of 5x103 lineage-negative cells per 
well. KLS enriched cells were cultured in 24-well plates containing 75% confluent 
irradiated OP9-DL1 or OP9–GFP with 6ng/ml IL-7 and 6ng/ml Flt-3. Stem cells 
were collected,  
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Table 5 Cell lines and culture media 
  Cell Culture Media  
BaF3  IMDM 10% FBS, 1% Penicillin/Streptomycin, 2% WeHi conditioned media  
WEHI-3B  IMDM 10% FBS, 1% Penicillin/Streptomycin  
OP9-DL1  alphaMEM, 20% FBS, 1% Penicillin/Streptomycin  
OP9-GFP  alphaMEM, 20% FBS, 1% Penicillin/Streptomycin  
HuT-102  RPMI, 10% FBS, 1% Penicillin/Streptomycin, 100U/ml hIL-2  
MT-2  RPMI, 10% FBS, 1% Penicillin/Streptomycin  
HEK 293T  DMEM, 10% FBS, 1% Penicillin/Streptomycin  
Phoenix  DMEM, 10% FBS, 1% Penicillin/Streptomycin  
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washed and plated on fresh irradiated OP9 cultures every 7 days. Lymphocytes 
were transferred to freshly irradiated OP9-DL1 cells and analyzed by flow 
cytometry for T- and B-cell differentiation markers every 7 days as described187. 
OP9-DL1 cells were maintained in culture as previously described. Cells were 
maintained in culture with alpha-MEM media with 20% FCS and 1% pen/strep in 
100cm plates.  
 
Additional Cell lines  
Hut-102 and MT-2 cell lines were obtained through the AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH. All cell lines 
were maintained in the recommended media (Table 5).  
 
In vitro Kinase assay 
Kinase assays were performed using a LANCE®Ultra time-resolved 
fluorescence resonance energy transfer (TR-FRET) from Perkin Elmer. Assays 
use a Europium chelate donor fluorophore-conjugated antibody, PT66 (Eu), 
against the P-tyrosine of substrate ULight-JAK-1 (Y1023), which is a short 
peptide sequence from JAK1 that is phosphorylated by JAK3. The ULight 
substrate has a small molecular weight acceptor dye with red-shifted fluorescent 
emission. This assay was optimized with recombinant human JAK3 (Signal 
Chem, Inc, amino acids 781 to the carboxy-terminus) containing only the kinase 
domain. Wild type or mutant JAK3 enzymes were purified from BaF3 cells by 
immunoprecipitation. Enzymes were incubated in Lance JAK3 assay buffer with 
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10 nM ULight-JAK-1 (Y1023) and 20µM ATP. Kinase reactions were terminated 
after 1 hour by the addition of 2x detection mixture containing PT66 Eu (8uM 
final) and EDTA (6mM final). After 30 min incubation in the detection mixture, 
FRET was detected at 665 nm after excitation at 340 nm using Perkin Elmer’s 
Victor V Plate Reader.  
  
Murine in vivo procedures 
Bone Marrow Transduction and Transplantation  
 For bone marrow transduction transplantation (BMTT), a single cell 
suspension of bone marrow cells was prepared from the tibias and femurs of 6 
week old Cdkn2aKO mice. The red blood cells were lysed with erythrocyte lysis 
buffer (Buffer EL, Qiagen) as explained above. Cells were then spin transduced 
every 2 days with MIG-JAK3 expression virus containing WT, E183G or A572V 
mutations with 6ug/ml polybrene. Between spin transductions, cells were cultured 
at 5 x105 cells/ml in DMEM with 15% FBS, 10µg/ml mIL-6, 100µg/ml mSCF, 
6ug/ml polybrene, and 1% pen/strep for 5 days. 2x106 transduced bone marrow 
and 5 x105 CD45.1 supporting cells were injected retroorbitally into lethally 
irradiated (9Gy) recipient CD45.1 mice (Figure 18). CDKN2AKO mice were 
obtained from the National Cancer Institute’s mouse repository188. Peripheral 
blood of transplanted mice was obtained every 1-2 months and analyzed for 
expression of GFP, CD45.1 and CD45.2 by flow cytometry. Mice were sacrificed 
as necessary due to morbidity of disease and thymus, spleen and bone marrow 
were removed for further analysis.  
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Secondary transplantion 
 2x106 splenocytes isolated from primary BMTTs were retororbitally injected 
into sublethally irradiated (7Gy) recipient CD45.1 mice. Mice were sacrificed as 
necessary due to morbidity of disease and thymus, spleen and bone marrow 
were removed for further analysis.  
 
Histology and peripheral blood analysis  
 Peripheral blood smears or sections of spleen or bone marrow were fixed in 
10% formalin for 24 hours at room temperature prior to embedding in paraffin 
and sectioning. Sections were counterstained with hematoxylin and eosin (H&E) 
by the Translational Pathology Shared Resource core at Vanderbilt Medical 
Center.  
Assessment of JAK3KO complete blood cell counts was performed on 
peripheral blood obtained by retro-orbital bleed with the HEMAVET HV950FS 
blood analyzer (Drew Scientific, Inc) on mice 4 and 11 weeks of age128, 129, 186. 
 
Xenograft and engraftment 
 NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were acquired from Jackson 
Laboratory. These mice are severely immunocompromised and lack mature T 
cells, B cells, or functional NK cells, and are deficient in cytokine signaling189.  
NSG mice were lethally irradiated at 2.5Gy and intraperitoneally injected with 5 
x106 primary ATLL cells obtained from frozen buffy coat samples. Peripheral 
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blood of mice was obtained retroorbitally every month and tumor spread was 
monitored by flow cytometry with specific antibodies against human CD45 and 
human CD3 antigen. 
 NSG mice were subcutaneously injected with 10 x106 BaF3 cells stably 
expressing WT, L156P, E183G, or A572V JAK3.  The injection site was 
monitored weekly for tumor growth and daily after palpable tumor was observed. 
Mice were sacrificed when palpable tumor was 1 cm in size. Peripheral blood of 
mice was obtained retroorbitally every week and tumor spread was monitored by 
flow cytometry of the peripheral blood for GFP expression. 
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CHAPTER III 
 
 
JAK3 MUTATIONS IN ATLL 
 
Background and significance 
Chemotherapy and monoclonal antibody treatments do not alter the 
aggressive clinical course of ATLL. A long latency period of as much as 50 years 
suggests that a multistep mechanism for leukemic development is involved in the 
development of ATLL, although the critical events in the progression have not 
been fully elucidated. Targeted therapeutic treatments would be facilitated by the 
discovery of genes and pathways that drive or initiate ATLL. So far, these targets 
have not been fully determined. 
The IL-2 signaling pathway is known to play a prominent role in ATLL 
pathogenesis; mutational analysis of IL-2 signaling pathway components should 
yield potentially interesting results. Janus Kinase 3 (JAK3) activating mutations 
have been identified in other leukemias and lymphomas. Until this study, all 
previously characterized activating mutations were found within the 
pseudokinase domain5, 6, 133, 138, 146. Subsequent to our findings, mutations 
between the FERM and the SH2 domains were identified in T-ALL cell lines. 
These mutations were characterized and identified in, KARPAS45 and SUPT1 
cells, (respective JAK3 mutations are A251T and R272H)190. As T cells are 
dependent on JAK3 for both development and function, it is unlikely that these  
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Figure 2 JAK3 FERM mutations identified in ATLL. Schematic and alignment of 
JAK3 proteins show 7 JAK homology (JH) domains, JH6-7 comprise the FERM 
domain (orange). Residue numbers and major structural domains are shown. 
Sequencing revealed three mutations (orange boxes) in 4 of the 36 ATLL patient 
samples analyzed. L156P and R172Q were identified in one patient each and 
E183G was found in 2 patients. The mutations occurred in residues higly 
conserved across mammalian species. The schematic shows JAK3 containing 7 
JAK homology domains with JH6-7 comprising the FERM domain (orange). The 
three ATLL-derived mutations are shown in orange boxes.  The mutations occurred 
in highly conserved residues.  
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mutations would induce loss of JAK3 kinase function. More likely, they will be 
gain of function mutations further supporting our findings. Germline SCID JAK3 
point mutations occur in the FERM domain and abolish binding to γc111. There is 
also a rare SNP, P132T, which has inconsistently been shown to have a limited 
increased activity compared to WT and may play a role in the development of 
acute megakaryocytic leukemia.  
 
Results 
Identification of JAK3 mutations in ATLL patient samples  
Thirty-six ATLL patients were analyzed for mutations in the JAK3 gene by 
heteroduplex analysis, PCR, cloning, and sequencing5, 191. Sequence variants 
were identified in 4 patients (11%) that were not present in SNP databases or in 
23 ethnically matched control individuals192 192. Some of our samples were 
purified leukemic blasts from apheresed patients and some were mixed with 
normal cells within buffy coat samples. These mutations occurred in the amino 
terminal FERM domain. L156P (leucine to proline), R172Q (arginine to 
glutamine), and E183G (glutamate to glycine) missense mutations occurred in 
residues that are highly conserved across mammalian species (Figure 2 orange 
boxes). All three were somatically acquired and clustered within the FERM 
domain of JAK3. One patient was determined to be a carrier of the P132T SNP 
(Table 2). Additionally, a cluster of SNP variants within introns 2-5 was identified 
for 3 ATLL patients (data not shown). So far, these are the only characterized 
activating mutations ever identified within the  
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Figure 3 Frequency of tax approximates the frequency of mutations in one 
ATLL patient. One patient was identified as having a JAK3 L156P mutation at 
a frequency of approximately 10% as estimated by number of subclones 
containing the mutations. Genomic DNA for this patient was quantified for tax 
copies (blue diamonds) using quantitative PCR (qPCR). Tax levels are roughly 
8.7% of the control Chromosome 11 short tandem sequence (STS) (red 
squares) levels. Tax frequency was calculated as the difference between mean 
Ct for tax (1 copy) and the mean Ct for STS (2 copies), which was 1:32. Tax 
quantification approximates the frequency of leukemic cells in the buffy coat 
sample. We conclude that the leukemic cell frequency is approximately the 
same as the frequency of L156P mutation. 
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FERM domain of JAK3. While more mutations were identified, this was the only 
cluster of mutations within the patients studied. This suggests a potential 
preference for the development of mutations within the FERM domain in ATLL. It 
could be further conjectured that these mutations may be necessary for T cell 
specific leukemia/lymphomas.  
 
FERM domain mutation are clonal in primary tumor 
The frequency of the allele for carrying the L156P mutation from one 
patient sample was roughly 10% based on the proportion of mutant positive 
clones sequenced during the initial analysis. This is roughly the same frequency 
as the genomic PCR product of the viral gene tax as determined by qPCR, which 
was 8.7% (Figure 3). This data also implies that this HTLV-1 positive tumor 
sample is clonal for the L156P mutation. As previous studies have shown that 
transformation by HTLV-1 in vitro progresses from a polyclonal to a monoclonal 
with respect to proviral integration, it is possible that mutations in JAK3 have the 
potential to induce clonal outgrowth. 
 
JAK3 FERM domain mutations in ATLL patients do not show loss of 
function 
JAK3KO fetal liver (Lin-c-Kit+) hematopoietic progenitor cells (LSKs) were 
isolated and co-cultured with OP9-DL1 stromal cells187. OP9-DL1 stromal cells 
with the addition of mIL-7 and mFlt3 were shown to induce wildtype LSKs from 
C57/B6 mice to differentiate into T cells193.  
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Figure 4 JAK3 expression in culture rescued T cell development. A) Graph 
shows cell counts over time in OP9-DL1 co-culture.  JAK3ko progenitor cells 
transduced with empty MSCV failed to proliferate and differentiate.  Proliferation 
was rescued for those progenitors transduced with WT or mutant JAK3. This 
graph shows cell counts over time in OP9-DL1 co-culture.  JAK3ko progenitor 
cells transduced with empty MSCV failed to proliferate and differentiate.  
Proliferation was rescued for those progenitors transduced with wild type or 
mutant JAK3. B) Representative image of splinkerette PCR C) and TCRβ 
rearrangement for clonality on T cells differentiated in coculture with OP9-DL1 
cells.  
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JAK3KO cells transduced with empty MIG virus did not proliferate as expected, as 
JAK3KO mice do not develop T cells (Figure 4A). WT JAK3 expression as well as 
expression of L156P, R172Q, E183G and A572V all showed consistent cell 
growth; thus, loss of function of JAK3 due to these newly identified mutations in 
ATLL was eliminated as a possibility. 
Samples showed some moderate clonality by splinkerette insertion site 
analysis disregarding MSCV internal fragment. These were then subcloned into 
pGEM-T-Easy vector for sequencing analysis. After a BLAST search, none of the 
insertion sites was assessed to be of any relevance to the expansion of the 
disease. Examples of insertion sites are tubulin tyrosine ligase-like family 
member 11, ring finger protein 166, and hypothetical protein LOC228677. Each 
clone sequenced had a unique insertion site. This level of apparent clonality may 
be due to beginning the experiment with few cells and low transduction 
efficiency. Only a very small group of cells would commit to T cell differentiation 
and increased growth presenting with artificial clonality. This is not due to 
advantageous changes in gene expression because of insert site. Insertion 
location should not be considered paramount to the population expansion (Figure 
4B). No obviously clonal TCRβ rearrangement was observed in differentiated T 
cells (Figure 4C).  
JAK3KO LSKs transduced with wild type (WT) JAK3, an activating mutant 
(A572V), or any of the three ATLL mutations proliferated and differentiated into 
CD4 and CD8 double positive cells by day 14 (Figure 5A). Differentiated LSKs 
showed JAK3, STAT5 and P-STAT5 expression at levels comparable to wildtype  
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samples (Figure 5B). From these experiments, it was determined that the ATLL 
JAK3 mutations occurring in the FERM domain can rescue T cell development in 
JAK3KO LSKs and do not cause loss of JAK3 function. Interestingly, T-cell 
differentiation and proliferation did not occur in the transduced cells when IL-7 
was omitted from culture. IL-7 is key to early T cell development. However, these 
mutations do not induce loss of function in this assay as indicated by the 
continued requirement of cytokine stimulation. This implies that these JAK3 
mutants are appropriately interacting with the IL-7 receptor.  
  
ATLL derived FERM domain mutations do not inhibit JAK3 binding to γc 
The FERM domain of JAK3 binds to the cytoplasmic tail of the γc protein, 
which is a key component of interleukin receptors IL2R, IL4R, IL7R, IL9R, IL15R, 
and IL21R. Co-immunoprecipitations of JAK3 mutants with γc from transduced 
BaF3 cells showed that JAK3 containing L156P, R172Q, E183G, and A572V 
mutations bound γc to approximately the same extent as wild type JAK3. These 
FERM domain mutations do not appear to inhibit JAK3 binding to the γc subunit 
of the receptor, whereas the previously described inactive SCID mutant Y100C 
has been shown to abolish JAK3 receptor binding117. These experiments showed 
that the ATLL JAK3 mutations in the FERM domain did not cause loss of function 
but also did not alter the binding function of the FERM domain (Figure 6). 
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Figure 6 Mutant JAK3s show binding to γc comparable with that of WT JAK3.  
JAK3 (106 kDa) and γc (48 kDa) co-immunoprecipitation (IP) and Western blot 
(WB) analysis are shown.  BaF3 cells were transduced with WT JAK3 or mutant 
JAK3s and then subjected to IP.  Blots were performed with infrared dye labeled 
secondary antibodies and were quantified.  The quantification is shown in bar 
graphs. The proteins precipitated were quantified and normalized to the 
comparable band seen for WT JAK3.  IP data represents two independent 
experiments. 
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Discussion 
The FERM domains in various proteins, such as focal adhesion kinase 
(FAK), play a role in autoregulation of protein function and activity194. The 
function of several structural proteins involved in a diverse group of activities 
including endocytosis, exocytosis, motility, and microfilament formation are also 
closely autoregulated by FERM domain interactions118, 195-197. The major function 
of the JAK3 FERM domain, as previously investigated, is to bind the cytoplasmic 
tail of γc103. Here, three JAK3 FERM domain mutations were identified from 
genomic DNA isolated from ATLL tumor samples and kinase function was 
verified in culture. In screening thirty-six ATLL patients and twenty-three 
ethnically matched controls, three activating mutations in JAK3 were identified in 
highly conserved residues. Somatically acquired missense mutations L156P, 
R172Q, and E183G were studied. The E183G mutation was found in two 
different patients. One patient sample containing the L156P mutations was 
shown to have the same copy number of mutant JAK3 by number of mutant 
positive clones as presence genomic tax as determined by qPCR proving that 
the mutation is clonal for all of the tumor cells.  
All mutations analyzed clustered within the FERM domain of JAK3 whose 
previously described function is to bind the cytoplasmic tail of γc103, 111, 114, 117, 198. 
In humans, autosomal recessive severe combined immunodeficiency (SCID) is 
caused by loss of function of JAK3199. Previously identified mutations in the 
FERM domain of JAK3, D169E and Y100C, are loss of function mutations found 
in some SCID patients199. Loss of function due to any of these three ATLL 
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mutations in JAK3 was eliminated by transducing JAK3KO fetal liver Lin-c-
Kit+enriched hematopoietic stem cells (LSKs) with MSCV- WT or mutant JAK3 
virus after which these cells were co-cultured on irradiated OP9-DL1 stromal 
cells. JAK3KO LSKs transduced with wild type (WT) JAK3 or mutant JAK3 
rescued T cell proliferation and differentiation (Figure s 4 & 5). JAK3KO cells failed 
to proliferate or differentiate into CD4 and CD8 double positive T cells. A 
previously described activating mutant JAK3 A572V and the ATLL mutations 
rescued proliferative and differentiation defects in the knockouts bone marrow 
derived cells in culture5, 186, 187. Overall, these data show that these residues are 
not involved in the regulation of kinase receptor interactions and they do not 
inhibit cytokine stimulated function and T cell development.  
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CHAPTER IV 
 
BIOCHEMICAL CHARACTERIZATION OF JAK3 MUTATIONS  
 
Background and significance  
The IL-2 signaling pathway plays a prominent role in ATLL pathogenesis 
and JAK3 is a key component of this pathway. The FERM domain of JAK3 is 
known to function as the site of direct interaction with the cytoplasmic tail of IL-2 
receptor’s γc subunit but, as we have shown, this interaction is not altered by 
these specific mutations. Two different mechanisms for regulation of protein 
interactions by FERM domains were described, intermolecular and 
intramolecular regulation. For example, disruption of the FERM domain of FAK 
increases activity and promotes FAK signaling114. This shows that FERMs can 
have autoregulatory roles in addition to regulating interactions with other 
proteins. If specific mutations in the FERM domain of JAK3 increase function, 
this could imply a similar autoregulatory role as that seen in FAK114, 200, 201.  For 
an example of intermolecular interactions, the JAK3 FERM domain binds the γ 
subunit of the IL-2 receptor. Mutations from SCID patients abolish γc binding and 
thus kinase activity and an intact FERM domain is required for JAK3 binding of 
an ATP analog111. While the FERM domains mediate intermolecular interactions 
with cytokine receptor, they are also involved in intramolecular binding to JH1 
kinase domain, thereby maintaining kinase activity111. 
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Overexpression of JAK1, JAK2, and TYK2 in transient transfections gave 
rise to cell proliferation in BaF3 cells and considerably less so with JAK3. Only 
TYK2 and JAK1 provided cytokine independence after viral transduction. In the 
case of JAK1, this was dependent on expression of functional FERM and kinase 
domains. All stable expression lines showed an increase in STAT5 
phosphorylation in the absence of cytokine stimulations202. 
Previously, tyrosine auto-phosphorylation at the SH2-domain of JAK3 
were found to facilitate the interactions between JAK3-FERM domain and 
cytoskeletal proteins, demonstrating that the intramolecular interaction between 
FERM and SH2 domains of non-phosphorylated JAK3 prevented JAK3 from 
binding to structural protein villin. Tyrosine auto-phosphorylation of JAK3 at the 
SH2 domain decreased these intramolecular interactions and facilitated binding 
of the FERM domain to villin. Thus, they demonstrated the molecular mechanism 
of interactions between JAK3 and cytoskeletal proteins where tyrosine 
phosphorylation of SH2 domain acted as an intramolecular switch for the 
interactions between JAK3 and cytoskeletal proteins and was regulated by 
FERM domain interactions203. 
Localization of JAK1, JAK2 and TYK2 remain predominantly close to the 
membrane through an association with the cytoplasmic tail of cytokine 
receptors204, 205. In the absence of cytokine stimulation JAK3 has been described 
to localize to the nucleus. With low dose cytokine stimulation, JAK3 will localize 
to the cytosol and membrane. At high concentrations of IL-2 JAK3 localizes 
predominantly to the membrane in cell culture206, 207. 
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The FERM domain of JAK1 has been described based on homology to 
non Janus kinase FERM domains that have been solved including FAK and 
radixin. This study noted that the FERM domains of the JAKs are only remotely 
similar to the core ERM proteins and more closely resembles the FERM domain 
of FAK.  In fact there is quite a lot of divergence between the JAKs with JAK2 
and JAK3 being more closely related to FAK than are JAK1 and TYK2115. 
 
Results 
ATLL mutations increase phosphorylation of STAT5A in cell culture. 
MIG constructs expressing JAK3 mutant cDNA were developed by 
introducing mutations into the WT JAK3 using the Stratagene QuikChange kit 
and verified by direct sequencing. To determine the relative activity of mutant 
JAK3 to WT and a known activating mutation, A572V, the IL-2 signaling pathway 
was recapitulated in HEK 293T cells. HEK 293T cells are deficient for all 
components of the IL-2 signaling pathway. Because of this, each aspect of 
signaling can be manipulated and controlled. 
The IL-2 signaling pathway was established in HEK 293T cells by co-
transfecting plasmids that express each of the three subunits of the IL-2 receptor 
(α,β,and γc), STAT5A, and WT or mutant JAK3. Equivalent amounts of protein 
were expressed in each transfection as quantified by Western blotting with 
infrared dye-labeled secondary antibodies against IL2Rα, IL2Rβ, γc, STAT5 and  
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Figure 7 JAK3 FERM mutations cause increased phosphorylation of STAT5A in 
reconstituted IL-2 signaling in HEK 293T cells.  A) Western blots show P-STAT5A (92 
kDa), STAT5A and JAK3.  Lane 1 shows whole cell lysate of HuT-102 cell line.  STAT5A 
phosphorylation requires JAK3 and IL-2 (100 U/ml).  B) Is a graph of protein levels of 
each transfected component expressed as fold over endogenous Hut-102 levels. C) 
Graph shows quantification of Western blots; P-STAT5A protein per unit of expressed 
JAK3 protein.  Mutant JAK3s were compared to WT JAK3 in four independent co-
transfection experiments and showed consistently higher P-STAT5A levels (mean ± 
SEM) (top panel).  P-values were generated from Student t-test (two tailed).  The bottom 
panel shows P-STAT5A protein levels in co-transfection experiments with various other 
JAK3 mutants normalized to endogenous levels in Hut-102.  The K855A mutant causes 
loss of kinase activity in JAK3.  The Y100C mutation was found in a SCID patient and 
P132T is a SNP.  
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JAK3 (Figure 7A). Protein expression was not a variable in the quantification of 
phosphorylation. 
Phosphorylated STAT5A was quantified using a primary antibody specific 
to P-Y694 of STAT5A, a residue uniquely phosphorylated by JAK3208. Co-
transfection of the IL-2R components with STAT5A showed no P-STAT5A in the 
absence of JAK3, demonstrating the specificity of the phosphorylation site to 
JAK3. Co-transfection of IL-Rα, β, γc, STAT5A, and WT JAK3 induced P-
STAT5A only in the presence of exogenous IL-2 (100 U/mL). This was used to 
compare the relative activity of the mutant JAK3s.  
P-STAT5A levels were normalized to JAK3 protein expression and loading 
control protein from Hut-102 cells. The L156P JAK3 mutant did not show a 
statistically significant increase in P-STAT5A levels in this assay as compared to 
WT JAK3. Increased levels of P-STAT5A were found with mutant JAK3 co-
transfections in comparison to wild type JAK3 co-transfections for both E183G 
and R172Q (Figure 7C).  
To verify that the observed P-STAT5A was caused by increased JAK3 
kinase activity, a compound mutant was made, with the FERM domain mutation 
E183G and the catalytically inactive K855A mutation104, 111. This compound 
mutant expressed stable JAK3 protein to the same extent as WT but showed no 
phosphorylation of STAT5A in this assay. The K855A mutant causes loss of 
kinase activity in JAK3. When expressed in 293T cells K855A shows no STAT5A 
phosporylation. P132T, a common SNP found in 1% of the population, was also 
introduced into the JAK3 construct. The P132T mutations showed only slightly 
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increased levels of P-STAT5A as compared to WT JAK3 which were not 
statistically significant. STAT5A phosphorylation was diminished but not 
abolished with the Y100C SCID mutation. The Y100C mutant may retain some 
limited binding to γc when overexpressed. Reconstituted IL-2 signaling in 293T 
cells showed that the ATLL FERM mutations, E183G and R172Q, induced 
increased phosphorylation of STAT5A compared to WT JAK3.  
    
Mutant JAK3s confer cytokine independent growth in BaF3 cells 
To further establish this activating phenotype, BaF3 cells were transduced 
using recombinant MIG retroviruses expressing mutant or WT JAK3s and sorted 
for GFP+ cells. BaF3 cells require phosphorylation of STAT5 through IL-3 
signaling and become IL-3 independent when gain of function tyrosine kinases 
are expressed that signal through the same pathway179. Untransduced BaF3 
cells and those with WT JAK3 did not proliferate in the absence of IL-3 and died 
within 3 days of initial IL-3 withdrawal. As a result, all subsequent experiments on 
untransduced BaF3s and those transduced with WT JAK3 always included 
murine IL-3. BaF3 cells transduced with mutant JAK3s grew without IL-3 and 
were continuously passaged as stable cell lines. Although the L156P JAK3 
mutant did not show a statistically significant increase in P-STAT5A levels in the 
293T assay it did show activation in BaF3 cells (Figure 8). 
Retroviral integration sites were analyzed by splinkerette and showed that 
the stable BaF3 lines expressing mutant JAK3s were mostly polyclonal.  Of those  
  
 
55 
 
 
Figure 8 Mutant JAK3s confer cytokine independence in BaF3 cells.  BaF3 cells 
transduced with JAK3s were counted daily after IL-3 withdrawal.  WT JAK3 
transduced and untransduced BaF3s did not survive unless supplemented with IL-3.  
Those transduced with mutant JAK3s became cytokine independent by 7 days.  
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that showed clonal integration, no integrations were found near genes that could 
account for cytokine independent growth (Figure 9). 
 
Mutations in JAK3 alter protein signaling 
JAK3 stimulates multiple downstream signaling pathways leading to the 
phosphorylation of several proteins important for the regulation of proliferation, 
inhibition of apoptosis and cell cycle progression.  To determine which 
downstream targets of JAK3 activity were affected, the phosphorylation states of 
STAT5 (Y694), STAT3 (Y705), ERK1/2(T202 and Y204), and AKT (S473) were 
analyzed after acute withdrawal of IL-3 (Figure 9). The IL-3 withdrawal cultures 
were divided in two and IL-3 was added to one group before preparing whole cell 
lysates or immunoprecipitates. Phosphorylation of Y980, a residue in the 
activation loop of JAK3 that is autophosphorylated and positively regulates 
kinase activity109, 209, was minimal in WT JAK3 but constitutive in all three mutant 
JAK3s. P-Y980 was not observed in BaF3 cells expressing the E183G/K855A 
compound mutant JAK3, confirming that Y980 is a site of autophosphorylation, 
and IL-3 did not consistently affect this phosphorylation. P-STAT5 was detected 
in all the BaF3 cells expressing mutant JAK3s but not in untransduced BaF3 cells 
or BaF3 cells transduced with WT JAK3 after IL-3 was withheld. P-STAT5 was 
increased after the addition of IL-3, which is induced in this system through 
JAK2. AKT phosphorylation at S473 was increased in all the mutant JAK3 
expressing BaF3 cells compared to untransduced and WT JAK3 expressing 
BaF3s regardless of cytokines status. ERK1/2 and STAT3 phosphorylations were  
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Figure 9 Viral insertion site analyses in BaF3 
cells.  Genomic DNA was isolated from IL-3 
independent BaF3 cells and subjected to 
splinkerette PCR analysis to determine viral 
insertion sites. 
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present in a different pattern than JAK3, STAT5, and AKT. P-ERK1/2 was not 
detectable in the mutant JAK3 expressing cells without the presence of IL-3 and 
STAT3 was minimally phosphorylated without IL-3. This basal level of P-STAT3 
was the same in untransduced BaF3 and in cells expressing WT or mutant JAK3 
and could be stimulated with IL-3 addition.  
In summary, the phosphorylation states of JAK3, STAT5, and AKT were 
correlated with cytokine independent growth of mutant JAK3-expressing cell 
lines, whereas ERK1/2 and STAT3 phosphorylation states were not (Figure 10). 
Although the L156P JAK3 mutants did not show a statistically significant increase 
in P-STAT5A levels in the 293T assay, it did show biologic activity in BaF3 cells. 
The events that correlated with the cytokine independent growth were 
identified as STAT5 and AKT phosphorylation more so than that of ERK or 
STAT3.  
 
The introduction of JAK3 to BaF3 cells does not change cell cycle 
profile 
In an effort to determine if these activating mutations were hyper-
proliferative, cell cycle profiles were determined by PI staining and analyzed by 
flow cytometry. Cell lines that expressed JAK3 mutants grown without IL-3 were 
not impaired in their proliferation, as they showed cell cycle profiles comparable 
to BaF3 cells maintained in IL-3 (Figure 11). Flow cytometry histograms show 
propidium iodide staining of JAK3 transduced BaF3 cells. The percentage of cells 
in each stage of the cell cycle is expressed as a percentage of total cells above  
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Figure 10 Protein signaling in BaF3s. BaF3 cells expressing mutant JAK3s 
showed constitutive autophosphorylation and phosphorylation of STAT5 
(Y694) and AKT (S473) without IL-3.  All western blot analyses were 
performed using whole cell lysates except pSTAT3 and pJAK3, which were 
blotted from immunoprecipitates.  
 
  
 
60 
 
 
Figure 11 Cell cycle analysis of BaF3 cells. Flow cytometry histograms show 
Vybrant dyecycle violet staining of stable BaF3 lines.  Proportion of cells in 
cell cycle stages G1 or S/G2 are expressed as percentage of total cells 
above the peaks.  Mutant JAK3 transduced BaF3 cells were maintained 
without IL-3.  A572V, L156P, and E183G mutants showed comparable 
proportions of cells in S/G2 phase. R172Q is more closely comparable to WT 
JAK3 expressing BaF3 cells. Data shown are representative of two 
independent experiments.  
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the peaks. Mutant JAK3 transduced BaF3 cells were maintained without IL-3 and 
showed comparable proportions of cells in S-phase as the untransduced BaF3s. 
R172Q mutant JAK3 transduced BaF3 cells showed increased cell numbers in S-
phase.  
 
Mutant JAK3 proteins are more stable in cultured cells 
The JAK3 proteins were shown to undergo proteasome-mediated 
degradation after activation210, 211. Therefore, the stability of WT and mutant 
JAK3 proteins in the BaF3 cells were analyzed. Cycloheximide, an inhibitor of 
protein biosynthesis, was applied to BaF3 cells and quantitative western blots for 
JAK3 protein were performed. JAK3 protein expression was quantified using 
fluorescent secondary antibodies and protein signals curves were plotted verus 
time for the mean of five independent experiments. Linear regression analysis of 
the curves showed that the mutant JAK3s clustered together with similar decay 
times (A572V, t1/2=4.3 h; L156P, t1/2=3.2 h; R172Q, t1/2=4.1 h; E183G, t1/2=4.5 h), 
whereas WT JAK3 decayed more rapidly (t1/2=1.96 h). In fact, the mutant JAK3 
proteins had half-lives as much as 2-fold greater than WT JAK3 protein (Figure 
12).  
 
Degradation of activated JAK3 is not regulated by the lysosome 
It was postulated that the increased stability is due to the activated 
phenotype of the JAK3. To determine if this activation was due to loss of 
regulation, BaF3 cells expressing WT or mutant JAK3 were treated with  
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Figure 12 JAK3 stability after cycloheximide. Semi-log graph shows JAK3 protein in 
BaF3 cells expressing WT or mutant JAK3 after treatment with 100µg/ml 
cycloheximide for 0, 0.5, 1, 2, and 3 hours.  The respective half-lives were 
calculated from linear regression of five total experiments (R2>0.90).  A572V, 
L156P, E183G, and R172Q are all significantly more stable than WT JAK3.  
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chloroquine and JAK3 expression was determined by western blot. There was no 
noticeable difference in JAK3 expression one hour post chloroquine treatment.  
By four hours, there was a slight decrease of JAK3 expression at concentrations 
of 100 and 200µM chloroquine for E183G and A572V. By 24 hours, all groups 
demonstrated an obvious decrease in JAK3 after treatment with 25µM 
chloroquine, which was more pronounced for the mutant JAK3s. These data 
imply that activated JAK3 degradation was not lysosomally regulated (Figure 13). 
 
Degradation of activated JAK3 is regulated by the proteasome 
To further characterize the mechanism of activated JAK3 degradation, 
BaF3 cells expressing mutant or WT JAK3 were treated with the cell-permeable 
proteasome inhibitor MG132. Data shown are representative of two individual 
experiments. In contrast to the lysosomal inhibitor, treatment with 10µM of the 
proteasome inhibitor MG132 did not show a decrease in the abundance of JAK3 
in both A572V and E183G transduced BaF3 cell lines. These data verify that 
activated JAK3 is regulated by proteasomal degradation. Interestingly, both the 
WT and the kinase dead K855A mutant did show a slight decrease in protein 
expression after treatment with MG132 in as early as 30 minutes. This reduction 
in JAK3 expression remained consistent from 0.5 to 4 hours. The combination of 
these data implies that non-activated JAK3 degradation may be regulated by 
both the proteasome and the lysosome, whereas activated JAK3 may only be 
regulated by the proteasome (Figure 14).  
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Activated JAK3 localizes away from the nucleus   
When analyzed by immunoflourescence, WT JAK3 protein in BAF3 cells 
was present ubiquitously throughout the cell. In contrast, the activating mutant 
E183G was localized strictly outside of the nucleus. Previous studies have shown 
that activated JAK3 is known to interact with actin binding proteins and facilitate 
interleukin 2-induced cytoskeletal remodeling and wound-repair206. It is 
reasonable to hypothesize that JAK3 is sequestered within cytosolic and 
membrane bound protein structures only when in an activated conformation. 
Additional forms of regulation of JAK3 may be by conformation-dependent 
changes in subcellular localization (Figure 15). 
 
JAK3 mutations confer increased in vitro tyrosine kinase activity  
WT or mutant JAK3s were immunoprecipitated from BaF3 cells and were 
incubated with a peptide substrate conjugated to fluorescent beads. 
Phosphorylation was detected by Förster (or fluorescence) resonance energy 
transfer (FRET) between the fluorophore-conjugated phospho-specific antibody 
to the acceptor dye on the substrate. The assay parameters were established 
and optimized using a recombinant kinase domain of JAK3. Incubation of 
immune complexes with the peptide substrate without ATP resulted in 
background counts. With the addition of 20µM ATP for 60 minutes at 24°C, 
counts were detected using recombinant purified JAK3 (a truncated protein  
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Figure 15 E183G mutant JAK3 localizes away from the 
nucleus in BaF3 cells.  WT and E183G transduced BaF3 
cells were stained for JAK3 and DAPI . These cells were then 
imaged with a confocal microscope.  In WT-JAK3 transduced 
cells, JAK3 is ubiquitously expressed. E183G –JAK3 is 
localized away from the nucleus. 
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expressing the kinase domain only), WT JAK3, and each of the mutant JAK3s. 
No kinase activity was detected in immunoprecipitations with isotype control IgG 
from WT JAK3-transduced BaF3 cells, untransduced BaF3, or the compound 
mutant, E183G/K855A (E/K). Significantly, mutant JAK3 proteins showed 
increased enzyme activity compared to WT JAK3 (P<0.001 by Student t-test). 
WT JAK3 activity was less than that of the truncated JAK3 protein but was 
increased compared to IgG control (P=0.008). 
A representative immunoprecipitation (IP) of JAK3 is shown in Figure 16B 
after the kinase assay. This was also probed using 4G10, a pan P-tyrosine 
antibody, and a specific antibody against P-Y980 of JAK3209. JAK3 showed 
autophosphorylation and kinase activity, as determined by phosphorylation of 
JAK3 tyrosine 980 in WT and mutant JAK3s, but not the compound mutant 
E183G/K855A. Interestingly, immune complexes that were resuspended in 
Laemmli buffer for SDS-PAGE immediately after the IP procedure showed P-
Y980 only for mutant JAK3 proteins and not WT. In contrast, immune complexes 
that were equilibrated in ATP and kinase buffer followed by SDS-PAGE showed 
P-Y980 in both WT and mutant JAK3 proteins. Thus, the Y980 
autophosphorylation assayed immediately after IP or in whole cell lysates was 
more predictive of enzyme activity than the SDS-PAGE after the kinase assay. 
This also suggested that autophosphorylation was taking place during the kinase 
reaction for WT JAK3 protein in vitro. Previous studies have shown that Y980 
autophosphorylation can be detected in JAK3 proteins with gain of function or 
loss of function mutations and may not be entirely predictive of substrate  
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Figure 16. JAK3 FERM domain mutations show increased kinase activity in vitro.  A) 
Direct determination of the kinase activity for FERM domain mutations using the 
Lance Ultra TR-FRET-based assay. Background counts were seen in assays without 
ATP addition (light gray bars), for BaF3 cells, and with immunoprecipitations using 
isotype control IgG.  Recombinant human JAK3 (50 pg) was used as a positive 
control.  Specific immune complexes of WT and mutant JAK3s showed kinase activity 
with ATP.  The counts are shown as the average of nine independent kinase assays 
(mean ± SEM).  Statistical comparison between mutant JAK3s and WT JAK3 showed 
significantly higher kinase activity in the mutants (P<0.001, denoted by asterisks).  WT 
JAK3 showed statistically significant increased activity compared to IgG control 
(P=0.008). B) Shows western blots of JAK3 from a representative immunoprecipitation 
and the detection of autophosphorylated JAK3 after in vitro assay.  4G10 is specific 
for phospho-tyrosine and the third blot shows a phospho-Y980 of JAK3.  Notably, a 
kinase dead compound mutant E183G/ K855A showed no autophosphorylation.  
 
  
 
70 
phosphorylation99. In fact, immunoprecipitated JAK3 proteins from transfected 
293T cells did not show consistent Y980 phosphorylation. 
 
Molecular modeling suggests an autoregulatory function for the 
JAK3 FERM domain  
The frequency of mutation within the FERM domain suggests an 
autoregulatory role for the FERM domain, inhibiting kinase activity in the absence 
of cytokine stimulation and activation. The crystal structure of the JAK3 kinase 
domain was solved without the FERM domain108. Because of this, the crystal 
structure of the FERM domain of Focal Adhesion Kinase (FAK) was used as a 
model for JAK3 FERM domain structure revealing a possible structural basis for 
this kinase autoregulation. The FERM domain of FAK is the closest evolutionarily 
related FERM domain to JAK3 that has been crystallized. Amino acid side chains 
from the FAK FERM were shown to directly contact the intramolecular kinase 
domain causing occlusion of the substrate pocket212.  
When comparing the FERM domain of JAK3 to that of FAK, it was found 
that the mutations overlap with the subdomain of FAK that was determined to 
directly interact with the kinase domain of FAK regulating the activity of FAK. 
These data indicate that the JAK3 FERM domain may play a similar 
autoregulatory role, suggesting that the FERM domain may not only bind the IL-2 
receptor but it may also directly interact with the kinase domain of JAK3. Upon 
JAK3 phosphorylation, the FERM domain may release constraints on the kinase 
domain allowing JAK3 activation. The three FERM domain mutations would likely 
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disrupt this interaction even in the absence of initial activation allowing the kinase 
domain to be constitutively active.  
This homology based molecular model of the JAK3 FERM domain, based 
on the crystal structure of the FAK FERM, shows that all three ATLL derived 
mutations are within the same subdomain of the FERM. This correlates with the 
subdomain of the FAK FERM known to regulate FAK kinase activity, suggesting 
that the JAK3 FERM domain may play a similar autoregulatory role. In previous 
studies, FERM domain mutations from SCID patients, D169E and Y100C, found 
that an intact FERM domain was required for JAK3 binding of an ATP analog111.  
Therefore, the JAK3 FERM was modeled by homology to the FAK FERM 
domain crystal structure. The crystal structure of the JAK3 kinase domain is also 
shown with an alignment to FAK. The asterisks denote those residues in FAK 
that directly contact the intramolecular FERM domain. The residues of the FAK 
FERM domain that contact the FAK kinase domain (Figure 17) align in the same 
region as the ATLL mutations. Interestingly, this region is mainly alpha helical 
and the ATLL mutations are predicted to be helix disrupting.  
The homologous residues in JAK3 are colored in yellow in the ribbon 
diagram, are at the surface available for binding, and not buried within the 
molecule, but only one of the six contact residues are conserved. The modeled 
JAK3 FERM structure suggests that the ATLL mutations could perturb the 
secondary structure required for autoregulation of kinase activity. Interestingly, a 
SCID mutation was described in this region as well, D169E, which causes 
decreased γc association and loss of kinase activity213. This SCID mutation is  
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Figure 17 ATLL FERM domain mutations align to autoregulatory region 
of the FAK FERM based on homology modeling.  ATLL mutations 
(orange) align with the F2 subdomain of the FAK FERM (blue) that 
autoregulates the kinase domain of FAK.  Asterisks denote residues of 
FAK FERM that contact the intramolecular FAK kinase domain.   
Molecular structure is based on the crystal structure of the FAK FERM 
domain.  Those residues that are mutated in ATLL patients are 
highlighted (yellow).  The JAK3 kinase domain (green) is shown as it 
would be oriented to the FERM domain.  Below it, the respective kinase 
domains of FAK and JAK3 are aligned.  The activation loop of the two 
proteins is in bold and the autoregulatory tyrosines, Y980 and Y981, are 
highlighted in orange. Asterisks show the residues of FAK that contact 
the intramolecular FERM.  The residues of JAK3 that align with these 
are shown in yellow. Model of the JAK3 FERM domain based on the 
crystal structure of the FAK FERM.  ATLL mutations identified in this 
study (orange) align with a subdomain of the FAK FERM that 
autoregulates the kinase domain of FAK. FAK FERM residues that 
contact the FAK kinase domain are denoted with asterisks. 
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only three residues away from a mutation (R172Q) that shows gain of function in 
our assays. These data suggest that the secondary structure of the JAK3 FERM 
domain is very sensitive to amino acid substitutions perhaps due to 
intramolecular contact with the kinase domain, analogous to FAK. 
 
Discussion 
The cell based assays and the in vitro kinase results support a gain of 
function activity for the mutant JAK3s. IL-2 signaling was reconstituted in HEK 
293T cells, which lack IL-2R proteins. The cell line HEK 293T was utilized to 
transiently co-transfect all three subunits of the heterotrimeric IL-2 receptor IL-
2Rα, β, and γc along with WT or mutant JAK3 and STAT5a. STAT5A 
phosphorylation (Y694) was increased with the addition of the activating 
mutation, A572V, and two of the FERM domain mutations, R172Q and E183G. 
Similar studies were done using the known SCID mutation, Y100C which was 
confirmed to have limited STAT5 phosphorylation. Were the Y100C mutation 
prevents receptor binding and R172Q and E183G most likely loose the ability to 
regulate kinase activity. These data demonstrate the potential dual regulatory 
function of the FERM domain of JAK3.  
To verify that the observed P-STAT5A was caused by alterations 
specifically in JAK3 kinase activity, a catalytically inactive kinase mutation, 
K855A, was introduced into a JAK3 construct with the E183G FERM domain 
mutation. This compound mutant expressed stable protein to the same extent as 
WT JAK3 but showed no phosphorylation of STAT5A. As expected, the P132T 
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SNP introduced into the JAK3 construct showed the same level of P-STAT5A as 
WT JAK3.  
Untransduced BaF3 cells and those transduced with WT JAK3 died after 3 
days in culture without IL-3. All of the BaF3 cells transduced with ATLL derived 
mutant JAK3s continued to grow in the absence of IL-3 cytokine and became 
cytokine independent by day 7139, 179. BaF3 cells transduced with any of the JAK3 
mutants continued to be passaged as stable cell lines without IL-3. Lysates 
prepared from cells where IL-3 was acutely withdrawn showed constitutive 
phosphorylation of STAT5 (Y694) and AKT (S493) and the phosphorylation of 
STAT5 was higher, even for mutants, in those lines when IL-3 was maintained in 
the media showing a distinct gain in functional activity in these JAK3 regulated 
pathways. BaF3 cells that expressed mutant JAK3s grew without IL-3 and were 
not impaired in their proliferation as they showed cell cycle profiles comparable to 
BaF3 cells maintained in IL-3 (Figure 8).  
Based on modeling of the FAK FERM domain, it can be hypothesized that 
the FERM domain of JAK3 interacts with the kinase domain similar to FAK and 
implies a similar autoregulatory role (Figure 17).  
From these observations, it can be speculated that the FERM domain of 
JAK3 functions in an autoinhibitory role when JAK3 activity is suppressed. Our 
results imply that when this suppressive function of the FERM domain is 
impaired, JAK3 is maintained in a near-constant activated state.  
This evidence would be enhanced by a more thorough evaluation of the 
effects of specific mutations on JAK3 autophosphorylation as well as evaluation 
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of the autoregulatory properties of the JAK3 FERM domain by determining the 
role of each individual residue in the FERM subdomain that may interact with the 
kinase domain.  
 JAK localization has previously been described as having predominant 
nuclear localization of JAK1, JAK2, and TYK2214-217.  But more recent studies 
have determined that JAKs are more often localized to the membrane and 
cytosol in the absence of stimulation204.  
 Janus kinases are generally believed to be present in unstimulated cells in 
an inactive form. Ligand-induced receptor oligomerization, such as from cytokine 
interaction with its specific receptor, serves as a trigger to signal the recruitment 
of JAKs to close proximity of the receptors. JAK functions may not be restricted 
to cell surface receptors. JAK2 has been identified as the kinase that associates 
with p97, a member of the ATPases associated with different cellular activities, 
which is involved in membrane fusion and assembly of the transitional 
endoplasmic reticulum218.  
 It is crucial not to use overexpressed proteins when subcellular localization 
is investigated since posttranslational protein modification processes and 
endogenous protein/protein interactions may become limited upon 
overexpression. This can lead to severe artifacts in subcellular localization. In 
addition, it is well known that overexpressed Janus kinases activate themselves 
and aggregate in the cytosol. 
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CHAPTER V 
 
JAK3 FERM MUTATIONS IDENTIFIED IN ATLL ARE WEAKLY 
ONCOGENIC 
 
Background and significance 
Long latency between initial infection and cancer development suggests 
that there are most likely multiple somatic mutations after the initial requirement, 
HTLV-1 infection until the development of ATLL. The in vitro assays described in 
previous chapters show that the JAK3 proteins with FERM domain mutations are 
more active kinases when compared to wild type JAK3.  
Previously the constitutively active A572V JAK3 mutation was shown to 
induce lymphoproliferative syndromes in murine bone marrow transplantation 
models191. Unfortunately, hyperproliferative lymphocytes from this transplant 
were not able to be  serially transplanted and thus were not shown to be 
oncogenic. In a murine bone marrow transplant model using either WT C57/B6 of 
JAK3KO, donor bone marrow was transduced with ATLL derived mutant JAK3s 
and lymphoproliferative disease was seen in only few individuals suggesting an 
extremely low penetrance of disease. Upon serial transplantation, the secondary 
recipients did not develop disease. It should be noted that because of the low 
number of primary illness, only three mice were used for secondary 
transplantation. It was therefore determined that JAK3 activating mutations alone 
cannot induce leukemia in vivo. The activating JAK3 mutation A572V, originally 
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identified in acute megakaryoblastic leukemia and later found in Natural killer/T-
cell lymphoma was not able to confer disease upon serial transplantation5, 6. As 
noted by Walters et al, this observation would suggest that JAK3 activation is 
acting in cooperation with other mutations to confer complete transformation. 
The CDKN2A locus encodes 2 cell cycle regulatory proteins, p14(ARF) 
(p19 in mice) and p16(INK4a), which share exon 2 but use different  promoters 
and first exons and alternate reading frames. Both proteins are commonly co-
deleted in a large variety of human cancers. Human genetic data suggest that 
both INK4a and ARF products are important tumor-suppressor proteins 221-227. 
The p14(ARF) and p16(INK4a) genes have both been implicated as tumor 
suppressor genes by frequent mutations, deletions, or promoter 
hypermethylation in a variety of tumors. One of the genetic events necessary for 
the development of ATLL is the inactivation of tumor suppressor genes such as 
p14(ARF), p16(INK4a) or p53. In one study it was shown that 25% of a small 
cohort of ATLL patients had both p14(ARF) and p19(INK4A) suppressed through 
either promoter methylation or gene deletion. Two percent of these patients had 
loss of p14(ARF) expression only. All of the patients with loss of p14(ARF) 
expression had shorter survival, similar to that of patients with the p53 mutation, 
constant with the inactivation of p14(ARF) plays a key role in the progression of 
ATLL219. Another study found that six out of nine cell lines had lost p16(INK4a) 
expression and only one out of nine lost p14(ARF)220. 
Likewise, mice lacking both p16(INK4a) and p19(ARF) (CDKN2A KO), or 
p16(INK4a) only (p16(INK4A) KO), or p19(ARF) only (p19(ARK) KO) are prone to 
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developing tumors spontaneously and are sensitive to carcinogens, albeit with 
differences in latency and tumor spectra 228-230. Cdkn2aKO mice primarily develop 
B-cell lymphomas and sarcomas but can also develop a variety of tumors231, 232. 
Because cancer is a disease of accumulated mutations it was decided to 
look for potential cooperation between JAK3 activation and other mutations 
described in ATLL. The relationships between alterations in the CDKN2A and 
ATLL were previously investigated. Modifications on the CDKN2A were 
described in ATLL, including point mutations, in 18.2% of the 44 patient samples 
analyzed164, 233. Alterations in the CDKN2A were detected in approximately 15 to 
20% of ATLL patients. Interestingly, most of the patients with CDKN2A 
alterations had the aggressive form of ATLL. p16(INK4a) is epigenetically 
inactivated in 5 ATLL cell lines. In one ATLL cell line exon 2 was deleted, 
preventing expression of both p14(ARF) and p16(INK4A)220. p14(ARF) mRNA 
expression was suppressed in 13 of 37 ATLL cases, among which 9 cases 
showed inactivation of both p14(ARF) and p16(INK4A)219. CDKN2A thus appears 
to be a major tumor suppressor gene and alterations in this gene may play an 
important role during late stages in the transformation process induced by HTLV- 
1234. The status of p14(ARF and p16(INK4A) is unknown for the four patient 
samples that contain FERM domain mutations.  
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Figure 18 Activating JAK3 mutations cooperate with the loss of 
CDKN2A in vivo. A) Bone marrow was taken from the tibia and 
fibula for CDKN2ako mice and transduced with MSCV JAK3 
retrovirus.  Cells were maintained in culture in the presence of 
cytokine and virus for 5 days before retroorbital injection in to 
lethally irradiated B6/CD45.1 recipient mice. B) Arrows indicate 
enlarged spleen and thymus, C) Survival curves of BMTT 
recipient mice expressing WT, A572V, or E183G JAK3. 
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Results 
The expression of activated JAK3 decreases rate of survival of 
Cdkn2aKO mice 
WT JAK3 and JAK3 mutants were introduced into MIG constructs which 
were then used to make high titer (106 pfu/mL) retrovirus using the Phoenix 
packaging cell line. These viruses were used to transduce the BaF3 cells in the 
preliminary studies discussed above. Hematopoietic bone marrow cells from 
C57B6 mice were transduced with either MIG-JAK3 WT or MIG-JAK3 mutant 
viruses and then transplanted into lethally irradiated C57B6-Ly5.2 recipients. 
Although these mice were monitored for illness, very few showed any 
recognizable signs of disease, even after analysis of thymi, spleen, and bone 
marrow by flow cytometric analysis (data not shown).  
Hematopoietic bone marrow cells from Cdkn2aKO mice were transduced 
with MIG-JAK3 WT or MIG-JAK3 mutant viruses and transplanted similarly into 
lethally irradiated C57B6-CD45.1 recipients (Figure 18A). In contrast, these mice 
developed palpable splenic tumors as early as 20 days post transplantation 
(Figure 18B). Because of the loss of both P16(INK4a) and p19(ARF) tumor 
suppressors, it was expected that all mice would eventually develop tumors. 
Remarkably, both the A572V and E183G transduction groups showed 
accelerated development of disease as compared to WT JAK3 transduced 
samples. Almost all of the mice analyzed developed large spleens (22/23 
measured), with a few also showing an increase in thymus size (7/12 measured).  
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All of the mice with larger thymi were from the E183G group while none were 
from the WT transductions (Figure 18C). 
 
Mice expressing activated JAK3 on a Cdkn2aKO background 
developed predominantly B-cell lymphomas 
CD4, CD8, CD25, CD44, CD19, B220, Gr1, and Mac1 extracellular 
membrane-bound expression levels were analyzed by flow cytometry and results 
were determined for GFP/CD45.2 positive cells only from spleen, thymus and 
bone marrow of each mouse. For E183G mice, 9 out of 11 samples analyzed 
showed GFP positive splenic tumors (Figure 19). Two of these also had large 
thymic tumors,as compared to WT derived tumors, where only 3 out of 10 tumors 
were positive for JAK3 transduction as determined by GFP expression. This 
suggests that expression of activated JAK3 provides a growth advantage in 
conjunction with loss of expression of p16(INK4A) and p19(ARF) in vivo. Most 
tumors were positive for either or both of the B-cell markers CD19 and B220. As 
Cdkn2aKO mice predominantly develop B-cell lymphomas, the BM from these 
mice may already be primed to develop in B-cell lineage.  
Analysis of tumor clonality also showed a predominantly B-cell 
rearrangement with only some tumors having obvious clonality (Figure 20A). 
Rearrangement at both the Immunoglobulin heavy chain (IgH) and T-Cell 
receptor beta (TCRβ) gene loci was necessary to determine the clonal orgin of 
developed tumors. Characteristic of early lymphoid differentiation, the resulting  
phenotypes can be analyzed with PCR amplification. PCR was used to analyze 
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Figure 20 CDKN2aKO BMTT PCR analysis of recombination. 
Genomic DNAs from splenic tumors were subjected to PCR with 
primers designed to amplify various junctions IgH and TCRβ . 
PCR products were separated in a 2% agarose gel. Genomic 
DNAs from B6 spleen, CDKN2aKO were used as a negative and a 
positive controls, respectively. A) PCR for IgH shows some B cell 
tumor clonality. B) Very little TCRβ rearrangement is observed 
and no T-cell clonality. 
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 the variable subunits of both IgH & TCRβ. Receptor expression during normal 
development is not typically clonal and a profile showing only one rearrangement 
suggests tumorigenesis resulting from mass proliferation in late-stage 
lymphocytes. There is an obvious lack of rearrangement in TCRβ. Most but not 
all samples showed, one or two distinct IgH rearrangements with corresponding 
clonality found by the insertion site analysis (Figure 20).  
 
Oncogenic cooperation between loss of Cdkn2a and activated JAK3 
as determined by secondary transplantation 
Tumors from two GFP positive WT JAK3 and four E183G primary tumors 
were injected into four and eight secondary recipients, respectively. All of the 
serial recipient mice developed tumors but seven of eight of the E183G 
transplants and one out of four WT secondary recipients maintained their JAK3 
expression. This suggests cooperation between the activated E183G allele that 
does not occur with simple overexpression of the WT JAK3 allele.  
 
Discussion 
Previously, it was described that alterations in CDKN2A may play an 
important role during late stages in the transformation process induced by HTLV- 
1 and that other mutations must be necessary earlier in the transformation 
process to induce leukemia234. Walters et al showed a pre-leukemic expansion of 
T-cells and megakaryocytes in transplanted bone marrow cells transduced with 
the A572V mutant as early as 6 weeks. They were unable to serially transplant 
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these cells, suggesting that this mutation is not oncogenic on its own. Thus, it 
can be inferred that cooperating mutations may be necessary to develop full 
blown leukemia. 
Expression of an activated allele of JAK3, E183G, in conjunction with the 
loss of Cdkn2a leads to a decrease in the survival rate and accelerated rate of 
tumor formation. The resulting tumors express a range of IgH and TCRβ 
phenotypes but are predominantly clonal for IgH rearrangement consitant with 
CD19 and B220 expression by flow cytometry. The expression of activated JAK3 
acts as a catalyst to accelerate tumor progression in the B-Cell 
leukemia/lymphoma prone Cdkn2a knockout cells. The addition of activated 
JAK3 decreases the mean survival rate in comparison to WT as would be 
expected if these mutations were oncogenic in nature.  These BMTT samples 
could also be analyzed for specific protein expression to analyze signaling 
pathways that may be disrupted via western blot, quantitative reverse 
transcription PCR (qRT-PCR) or immunohistochemistry.  
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CHAPTER VI 
 
JAK3 MUTANTS ARE SENSITIVE TO SPECIFIC INHIBITORS IN VITRO 
 
Background and significance 
The current life expectancy is roughly one year after ATLL diagnosis and 
>90% of patients succumb within that time. ATLL generally responds poorly to 
standard treatment. Chemotherapy and monoclonal antibodies directed against 
ATLL tumor markers were shown to have little effect. Previously we have 
identified three mutations that induce gain of function in JAK3 from ATLL tumors.  
Because ATLL is incredibly rare, it would useful to identify potential 
specific drug targets, such as activated JAK3, and use existing drugs against 
these targets, such as tofacitinib, in conjunction with current treatments. 
Tofacitinib (trade name Xeljanz, aka tasocitinib, CP-690,550; CP-690550; 
CP690550), an orally active immunosuppressant, is developed by Pfizer for the 
treatment of rheumatoid arthritis, inflammatory bowel disease, dry eyes, 
ankylosing spondylitis, psoriasis, psoriatic arthritis, and for the prevention of 
transplant rejection. Tofacitinib specifically inhibits Janus kinase 3 (JAK3), which 
has a pivotal role in cytokine signal transduction235. 
Other inhibitors such as BEZ-235 (Selleck), BKM-120 (Active Biochem), 
and CI-1040 against PI3K/mTOR, PI3K and MEK, respectively, inhibit 
downstream signaling targets of JAK3 activation. The effectiveness of these 
various inhibitors need to be evaluated as potential treatment options for ATLL.  
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During clinical trials for moderate to severe rheumatoid arthritis, tofacitinib 
was reported to induce a higher rate of leukopenia, neutropenia, anemia, and 
lymphopenia in patients treated with over 30mg twice daily as compared to lower 
doses236. This phenotype is similar to that seen in JAK3 knockout mice. The 
thymi of JAK3KO are small or completely absent revealing a defect in T cell 
development. JAK3KO mice also have limited B cell development. This deficiency 
is likely the result of a block at the pre-B/pro-B stage of B cell development and is 
likely to be due to the lack of signaling through the IL-7 receptor, which is 
necessary for B cell development112, 237, 238. In addition to its well-known roles in T 
cells and NK cells, JAK3 mediates IL-8 stimulation in human neutrophils. This 
may also relate to the increased neutropenia after tofacitinib treatment113.  
 
Results 
JAK3-specific tyrosine kinase inhibitor, tofacitinib alters 
phosphorylation and protein signaling  
The JAK3-specific inhibitor, tofacitinib, was tested on the BaF3 cells stably 
expressing mutant JAK3s239-241. BaF3 cells were cultured expressing WT JAK3 
or mutant JAK3s with 0.5, 2, or 4µM of tofacitinib or with solvent (DMSO) alone 
and probed for JAK3 protein, P-Y980 of JAK3, and P-STAT5A at 4 and 24 hours 
by quantitative Western blot analysis. The JAK3 and P-STAT5A protein levels 
were expressed as fold difference as compared to BaF3 cells treated with solvent 
alone. The BaF3 lines stably expressing mutant JAK3s showed a distinct,  
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Figure 21 JAK3-specific tyrosine kinase inhibitor, tofacitinib alters 
phosphorylation and protein signaling.  A) BaF3 cells transduced with 
mutant JAK3s were treated with tofacitinib at concentrations of 0, 0.5, 2.0 
and 4.0 µM and analyzed by Western blot analysis at 4 and 24 hours.  The 
Western blots and graphs that display their quantification are shown.  
Protein levels are expressed as fold over levels seen in cells treated with 
DMSO (solvent) alone.  JAK3 (106 kDa) protein expression was 
comparable to DMSO-alone but decreased in the mutant JAK3-transduced 
BaF3 cells.  P-STAT5 (92 kDa) levels decreased markedly with increasing 
concentrations of inhibitor. P-JAK3 (106kDa) levels were relatively stable. 
JAK3 is not phosphorylated in WT transduced cells so it could not be 
quantified. Tubulin (55 kDa), a loading control, remained relatively stable.  
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dose-dependent decrease in P-STAT5A. At 2µM, P-STAT5A levels were 
decreased by 80% for all BaF3 cells stably expressing mutant JAK3s. 
Untransduced BaF3 cells showed much lower P-STAT5A at steady state, and 
this quantity only decreased 30% at much higher concentrations (4µM) of 
tofacitinib; P-STAT5A in BaF3 cells transduced with WT JAK3 was similarly 
resistant to the effects of inhibitor. JAK3 and tubulin were quantified as well. 
BaF3 cells have STAT5 phosphorylation secondary to the IL-3/JAK2 signaling 
which may have variable sensitivity to tofacitinib in cell based assays even 
though JAK2 kinase activity is inhibited at concentrations comparable to JAK3 
inhibition in cell free enzyme assays102(Figure 21).  
Tofacitinib did not inhibit Y980 phosphorylation to the same extent as 
STAT5A phosphorylation. P-Y980 in the A572V mutant JAK3 was most sensitive 
but only decreased to 75% of basal levels at the highest concentrations (4µM) 
(Figure 21).  
 
Mutant JAK3s are sensitive to JAK3-specific tyrosine kinase 
inhibitor, tofacitinib  
The inhibitor induced a decrease in P-STAT5 thath correlated with 
decreased growth of these BaF3 cells. The IC50 curves demonstrated a 
noticeable difference between BaF3 cells expressing mutant JAK3s versus those 
expressing WT JAK3 and in the untransduced BaF3 cells. Untransduced BaF3 
cells and those expressing WT JAK3 were not as sensitive to tofacitinib and  
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Figure 22 Mutant JAK3s are sensitive to JAK3-
specific tyrosine kinase inhibitor, tofacitinib. Live 
cells were quantified by the MTT assay. Cell 
survival decreased with increasing concentrations 
of tofacitinib.  BaF3 cells expressing mutant JAK3s 
were susceptible to tofacitinib (IC50:  A572V, 0.22 
nM; L156P, 0.27 nM, E183G, 0.087 nM, R172Q, 
0.082 nM).  
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curve-fitting did not generate models with high correlation (R2>0.90). Mutant 
JAK3 expressing BaF3s showed consistent sensitivity to tofacitinib with similar 
curves (Figure 22).  
 
BaF3 cells expressing activated JAK3s are sensitive to inhibitors 
against JAK3 downstream targets 
JAK3 specific inhibitor WHI-P131(JAK3 inhibitor 1) and pan kinase 
inhibitor staurosporine also inhibit phosphorylation and JAK3 signaling.  HEK 293 
cells transfected with IL2RA, IL2RB, IL2RG, STAT5A and JAK3 were treated with 
100U/ml of hIL-2 and 0, 0.025, 0.1 and 0.25µM staurosporine.  All JAK3s showed 
decreased phosphorylation of STAT5A in response to an increase in 
staurosporine concentrations and were susceptible to treatment even at 
concentrations as low as 0.025µM (Figure 23). To further test if the effect of 
tofacitinib was JAK3 specific, BaF3 cells were treated with a second cell-
permeable JAK3 inhibitor, WHI-P131. WHI-P131 is an ATP-competitive inhibitor 
specifically against JAK3 that has no effect on JAK1, JAK2, or TYK2. Like 
tofacitinib, WHI-P131 inhibits cell growth to a greater extent in BaF3 cells 
transduced with activated JAK3 (data not shown).  
To further determine the signaling pathways that were affected by JAK3 
activation, transduced BaF3 cells were treated with inhibitors against 
downstream activation targets of the JAK3 pathway, inducing PI3K, mTOR, and 
ERK1/2. Cell growth was inhibited with BEZ-235. BEZ-235 binds the ATP-binding  
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Figure 23 P-STAT5 decreases with increased 
concentrations of staurosporine in transfected HEK 293T 
cells.  HEK 293T cells transiently transfected with all 
components of IL2R, STAT5A, and JAK3 were treated 
with 100U/ml hIL-2 for 24 hours then treated for 1 hour 
with concentrations of 0, 0.025, 0.1 and 0.25µM 
staurosporine. 
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Table 6 Mutant JAK3s are sensitive to JAK3, PI3K and mTOR 
inhibitors. Live BaF3 cells were quantified by the MTT assay 
after 24 hours on inhibitor. IC50 and goodness of fit (R2) values 
for each mutant transduced into BaF3 cells were calculated 
based on  best fit curves.  ND means IC50 could not be 
determined due to poor curve fitting models. Goodness of fit for 
all MTT assays as represented by R2 values are shown and 
95% confidence intervals for IC50s are shown. Data is a 
compilation of two experiments done in quadruplicate.  
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clefts of PI3K and mTOR inhibiting their activity.  MTT cell proliferation 
experiments were performed at concentrations of 0, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 
50, 100, 500, and 1000nM. Cell growth was inhibited with a pan-PI3K inhibitor 
PI3K, BKM-120.  MTT experiments were performed at concentrations of  0, 
0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 50, and 100µM. Cell growth was not 
inhibited by treatment with CI-1040, a non-competitive inhibitor of ERK1/2. MTT 
experiments were performed at concentrations of 0, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 
50, 100, 500, and 1000nM. Interestingly, the BaF3 cells expressing mutant 
JAK3s were sensitive to PI3K and mTOR inhibitors but not to an ERK1/2 
inhibitor. This finding is consistent with the STAT5A and PI3K/AKT pathways 
being active in the BaF3 cells expressing mutant JAK3 protein (Table 6). 
 
Tofacitinib inhibits STAT5 phosphorylation and JAK3 expression in 
cultured ATLL cell lines in the absence of a JAK3 mutation. 
Cell lines dependent on JAK3 for survival are susceptible to the JAK3 
specific inhibitor tofacitinib242. BaF3 cells stably expressing JAK3 mutants and 
two ATLL cell lines, Hut-102 and MT-2, which do not contain JAK3 mutations 
were treated with tofacitinib. The BaF3 lines stably expressing JAK3 mutants 
showed a dose-dependent decrease in P-STAT5, whereas untransduced BaF3 
cells showed lower P-STAT5 (50% of the levels observed in the control group 
treated with solvent alone) only at higher concentrations (4µM) of tofacitinib 
(Figure 21). BaF3 cells phosphorylate STAT5 by signaling through the IL-3/JAK2  
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Figure 24 ATLL cell lines Hut-102 and MT-2, are sensitive to JAK3 
specific tyrosine kinase inhibitor, tofacitinib.  A) Human ATLL cell 
lines, HuT-102 and MT-2, were also treated with tofacitinib.  P-
STAT5A was sensitive at even lower concentrations of the 
inhibitor.  Both cells showed decreased P-STAT5A with increasing 
levels of inhibitor.  JAK3 (106 kDa) protein also decreased 
whereas tubulin (55 kDa) levels did not. B) Quantification of JAK3 
and pSTAT5 for HuT-102 and MT-2 treated with tofacitinib.  
Protein lysates from the experiments similar to those shown in 
Figure 4 were blotted quantitatively for JAK3, STAT5, pSTAT5 and 
tubulin.  JAK3 and pSTAT5 protein quantity was normalized to that 
seen in cells treated with DMSO (vehicle) alone. 
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pathway. JAK2 was shown to be sensitive to tofacitinib at high concentrations. 
The phosphorylation of STAT5 in both Hut-102 and MT-2 cells was sensitive too 
the tofacitinib (Figure 24). Hut-102 and MT-2 cells treated with tofacitinib greater 
than 1.0µM died too rapidly to be analyzed (data not shown). For this reason, 
Hut-102 and MT-1 cells were treated with much lower doses of tofacitinib 0, 0.05, 
0.1,0.25, and 0.5µM and analyzed by western blot analysis at 4 hours. After 
tofacitinib treatment, JAK3 (106 kDa) protein expression was compared to DMSO 
only treatmentsa and was shown to be decreased in both MT-2 and Hut-102 
cells. P-STAT5A (92 kDa) levels decreased with increasing concentrations of 
inhibitor. Tubulin (55 kDa), a loading control, remained relatively stable (Figure 
24).  
 
Discussion 
All four activating JAK3 mutations characterized here were inhibited with 
two JAK3 inhibitors, tofacitinib and WHI-P131. Tofacitinib was one of the first 
JAK inhibitors to enter the clinic and was recently FDA approved for the 
treatment of rheumatoid arthritis. Our findings underscore the importance of this 
pathway in ATLL development and offer a therapeutic target for this incurable 
cancer. 
The diminished STAT5 phosphorylation also correlated with growth 
inhibition at concentrations that could be achieved in culture for both BaF3 cells 
and ATLL cell lines dependent on JAK3. The dose response data for BaF3 cells 
transduced with JAK3 mutations was found to be considerably lower than the 
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dose responses for untransduced BaF3 cells or BaF3 cells transduced with WT 
JAK3. Cell proliferation decreased with an increase in tofacitinib concentration in 
all BaF3 cell lines expressing JAK3 mutations, as well as ATLL cell lines, Hut-
102 and MT-2. 
STAT5 phosphorylation in both Hut-102 and MT-2 cells, both derived from 
ATLL patients, was sensitive to tofacitinib. Mutations in the JAK3 gene in Hut-102 
or MT-2 cells were not found, although both lines utilize JAK3 for signal 
transduction. Hut-102, an HTLV-1 positive ATLL derived cell line, requires 
exogenous IL-2 for optimal growth, and MT-2 cells contain an HTLV-1 integrant 
5’ of the IL9R gene which induces overexpression of the receptor. These high 
levels of IL-9R may signal through JAK3 without ligand.  
It should be noted that both of our ATLL cell lines have high basal 
expression of phosphorylated JAK3. In a preliminary assay MT-2 cells were 
shown to require JAK3 expression in a knockdown assay. MT-2 cells transduced 
with siRNA against JAK3 were not able to maintain viability with the loss of JAK3. 
Upon initial JAK3 knockdown, the cells were incredibly unhealthy in culture and 
when those cultures were analyzed days later JAK3 expression was reaffirmed 
indicating that JAK3 is required for continued cell proliferation (Figure 25). 
After treatment with WHI-P131, BaF3 lines stably expressing JAK3 
mutants showed dose-dependent decreases in P-STAT5. Untransduced BaF3 
cells showed lower P-STAT5 as compared to solvent alone and mutant 
transduced cells. These results were comparable to those seen with tofacitinib 
treatments.  
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BaF3 cells have STAT5 phosphorylation after treatment with IL-3 due to 
IL-3/JAK2 signaling, which may have variable sensitivity to tofacitinib in cell 
based assays. When tested in vivo, results may vary depending on the primary 
tumor sample and kinase inhibitor. 
Our findings thus underscore the importance of this pathway in ATLL 
development and offer a potential therapeutic opportunity for this incurable 
cancer. Further supporting this data, proliferation was inhibited in ex vivo primary 
ATLL tumor cells by the addition of nanomolar concentrations of tofacitinib243. It 
is possible that ATLL primary tumors samples with increased P-JAK3 will be 
growth inhibited in vivo when treated with kinase inhibitors such as tofacitinib. 
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Figure 25 HTLV-1 transformed cell line, MT-2, does 
not maintain JAK3 knockdown. RNA was isolated 
from MT-2 cells 5 and 12 days post transduction with 
lenti-virus expressing siRNAs against JAK3.  JAK3 
and GAPDH expression was determined by RT-PCR 
and run on a 2% agarose gel.  
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CHAPTER VII 
ACTIVATED JAK3 AS A TARGET OF DISEASE TREATMENT AND 
PREVENTION IN VIVO 
Background and significance 
Here, as well as in other studies, cell growth is inhibited in primary ATLL 
tumor cells treated ex vivo with tofacitinib at a nanomolar range243. BaF3 cells 
have increased cell proliferation in the absence of mIL-3 with the addition of 
JAK3 containing activating mutations L156P, R172Q, E183G, and A572V. This 
growth is also inhibited by treatment with tofacitinib. These in-cell studies support 
the efficacy of treatment with the oral JAK3 inhibitor tofacitinib. 
In vivo methods that most closely duplicate disease conditions are 
important for further understanding of disease progression and to test novel 
therapeutic treatments for ATLL.  
 
Activated JAK3 allows BaF3 cell engraftment 
Transduced BaF3 cells expressing WT, L156P, E183G, and A572V JAK3 
were engrafted into lethally irradiated immunocompromised NSG mice to 
determine the advantage of an activated JAK3 in vivo. All three activating 
mutations showed signs of tumor growth at the site of injection within one week 
(Figure 26). Engraftment was determined by flow analysis of the peripheral blood 
for GFP within three weeks. GFP expression at week three for WT was 1.1%, 
25.0% for A572V, 1.1% for E183G, and 7.65% for L156P in the peripheral blood. 
Mice injected with L156P, E183G, and A572V were sacrificed by 21 days due to 
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Figure 26 Activated JAK3 mutations allow engraftment into NSG mice. NSG mice 
were injected subcutaneously with 1x107 Stably transduced BaF3 cells. WT mice did 
not develop tumor.   A572V, E183G and L156P mice were all sacrificed after 
palpable tumor grew to more than 2 cm in diameter.    
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excessive tumor volume at the injection sight. A572V tumor volume was 1.5 cm2, 
with BM infiltration of 84.1%, and spleen infiltration of 79.5% on the day of 
sacrifice. E183G showed signs of external ulceration at the injection site, with a 
tumor volume of 1 cm2, BM infiltration of 84.6% and spleen infiltration of 80.85%. 
L156P tumor volume was 1cm2, with BM infiltration of 89.0% and spleen 
infiltration of 85.6%. Initially WT peripheral blood was 2.2% at one week. By 
week 2 this was down to 1.1%. No tumor was observed at the site of injection 
and no engraftment was seen in the BM or spleen for WT. These data indicate 
that only BaF3 cells that are IL-3 independent by transduction with activated 
JAK3 are able to engraft NSG mice.  
 
ATLL tumor protein signaling and generation of ATLL bearing mice  
Each ATLL tumor sample has an individual phenotype specific to that 
tumor, certain signaling characteristics may be common to all tumors. Protein 
expression of and phosphorylation status were analyzed for 25 primary ATLL 
samples for JAK3, STAT5, AKT, and tubulin by western blot (Figure 27).  STAT5 
and AKT were expressed in all samples, with a lower expression level of STAT5 
in 5 out of 25 samples and 3 out of 25 for AKT as compared to loading control 
Hut-102. JAK3 expression was less consistent, with high expression levels noted 
in only 10 of the 25 samples, although it was expressed in nearly all of the 
samples. Unfortunately, P-JAK3 is difficult to analyze in these samples due to the  
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method of protein processing used. Lanes 4, 7, 9, 10 and 11 had lightly visible P-
JAK3. It is anticipated that if these samples were immunoprecipitated in 
appropriate buffer that the quantity of P-JAK3 positive samples would be higher. 
AKT is phosphorylated in most samples. STAT5 and JAK3 phosphorylation 
status is less obvious. Lanes 1, 10, 11, 17, 19, 20, 21, 23, and 25 showed 
pSTAT5.  
Samples ATL31 (Figure 27, lane 11) expressing both JAK3 and STAT5 
with P-JAK3 and P-STAT5 and ATL3 (Figure 27, Lane 22), which does not have 
P-JAK3 and had minimal STAT5 and JAK3 were injected into lethally irradiated 
immunocompromised NSG mice244. Both of these samples formed tumors in  
these mice as established by flow cytometry with antibodies specific to human 
CD45 or human CD3. With incorporation of an inducible luciferase lentivirus it will 
be possible to follow the specific location of tumor formation and growth in vivo, 
with the intent to treat these mice with kinase inhibitors and monitor ATLL cell 
survival and tumor growth. Peripheral blood was used to monitor circulating 
human cells with specific flow antibodies in vivo (Figure 28).  
 
Discussion 
In vivo models are important for validating novel therapies especially in 
rare diseases when clinical data is limited. In the case of ATLL, this is especially 
true as the non-specificity of treatment could have rapid and dire consequences. 
Here we show that only BaF3 cells that are cytokine independent may engraft 
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into immunocompromised NSG mice. These mice rapidly develop the disease, 
and this is an efficient assay for testing potential treatment strategies specifically 
against activated JAK3s.  
 Every tumor will express its own unique phenotype and protein signature. 
Recently cancer treatments have started to become more specially targeted not 
just to the cancer type but also to the individual case. ATLL has a known initiating 
factor of HTLV-1 infection and expression of viral oncogenes. What remains to 
be determined is the additional mutations that are necessary for diseases 
progression. Here, we propose that JAK3 may be commonly activated in the 
majority of ATLL tumors. Both AKT and STAT5 are frequently phosphorylated 
across tumor samples, although it is more difficult to determine whether JAK3 is 
also phosphorylated in multiple samples. To further support this idea, ex vivo 
treatment with tofacitinib experiments have been performed on ATLL primary 
tumor samples; these cells have considerably less cell proliferation and have 
increased apoptosis.  Of course, there is still a need for a case by case 
determination of JAK3 presence and activity as some samples do not seem to 
express JAK3 at all. There is also the question of how effective this inhibition will 
be in vivo. NSG mice were injected with ATLL primary tumor that either had P-
JAK3 or did not express JAK3 at all. Of those that developed tumor, those 
tumors infiltrated multiple organs including the spleen, BM, liver and kidney.  
These mice did not develop thymic tumors as this is most likely due to the lack of 
a thymus in these animals.  
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Figure 28 Xenograft mouse model displays multiple organ engraftments of 
ATLL tumor. NSG were subcutaneously injected with 5x105 primary ATLL 
tumor cells. Most developed tumor within 13 weeks. 
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CHAPTER VIII 
 
SUMMARY AND FUTURE DIRECTIONS 
This study presents two novel findings. The first is the identification of 
activated JAK3 as a potential therapeutic target in the treatment of ATLL through 
the identification of three activating mutations. The second is a direct 
autoregulatory role of the FERM domain on kinase activity of JAK3.  
The primary goals of this work are to acquire a better understanding of 
how ATLL develops and to use that knowledge to determine more specific 
treatment options against this vicious disease. A molecular approach was taken 
to identify the potential source of signaling misregulation within the IL-2 signaling 
pathway. Three somatic missense mutations in JAK3 were identified out of the 
thirty-six ATLL patients screened L156P, R172Q, and E183G. These mutations 
occurred in the amino terminal FERM domain and may contribute to the 
development of ATLL. The in vitro and in vivo effects of these mutations were 
characterized.  
In vitro kinase assays and cell-based assays in OP9-DL1, HEK-293T, and 
BaF3 cells were used to determine potential alterations in JAK3 function with the 
incorporation of ATLL derived mutations. All three mutations were found to 
induce gain of function in JAK3: first in the differentiation of LSKs into T cells on 
OP9-DL1s, second in the increase of STAT5A phosphorylation in HEK-293T 
cells, and lastly in the cytokine independence and changes in phosphorylation of 
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JAK3, STAT5, and AKT in BaF3 cells. Gain of function from the addition of 
mutations to the FERM domain of JAK3 implies a novel autoregulatory role for 
the FERM domain on kinase activity. 
One important question is whether the JAK3 mutants require receptor and 
ligand for signal transduction. The phosphorylation of STAT5A in the 293T cell 
assay required IL-2 and hematopoietic stem and progenitor cells transduced with 
mutant JAK3s did not differentiate or proliferate in the absence of IL-7, implying 
that cytokine stimulation is required. In contrast, BaF3 cells transduced with 
JAK3 mutants grew and cycled without cytokines, suggesting that the JAK3s did 
not require ligand binding to receptors. These data imply some cell type 
specificity in the requirement for ligand in mutant JAK3 signaling. Other proteins 
recruited to the receptors could play a role in this signaling. This may have 
pathogenic significance since these kinases are recruited by IL-2Rβ and γc. 
JAK1 was co-transfected in the 293T assay but produced no change in IL-2 
dependence consistent with prior reports (data not shown)245. The observation of 
ligand dependent or independent growth is clinically important because if FERM 
domain mutations are found to require JAK3/γc utilizing ligand in T cells, then 
cytokines must signal either by autocrine or paracrine mechanisms. HTLV-1 
infected T cells do show increased expression of IL-2 and IL-9246. There is also 
evidence for IL-9 secretion from monocytes isolated from ATLL patients and in T-
cell neoplasms that resemble ATLL such as cutaneous T-cell lymphoma IL-7 
secretion by keratinocytes may support tumor cell growth247, 248.  
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To further understand how this activation alters JAK3 function, we looked 
at JAK3 stability, localization, and degradation. Previous work has described the 
localization as being predominantly nuclear until induced by cytokine, at which 
time JAK3 predominantly localizes to the membrane. Here, it was found that the 
activated JAK3 is localized away from the nucleus in BaF3 cells while the less 
active WT protein is predominantly nuclear. All activating mutations increased the 
stability of the protein regardless of the mutations being present in the FERM of 
pseudokinase domains implying that this is not due to the location of the 
mutations but perhaps more likely because of the activated phenotype 
associated with these mutations.  
The ATLL mutations are also highly informative for understanding the 
biochemistry of JAK3 kinase activity. The homology model based on the crystal 
structure of FAK showed that the ATLL mutations align with the FAK FERM F2 
subdomain that occludes and inhibits the activity of the FAK kinase domain and 
the FERM domain of JAK3 may have a similar autoregulatory role.  
Interestingly, the FERM domain mutations described here also increase 
the overall protein stability of JAK3. The increased stability may be related to the 
increased activity of JAK3 since the FERM domain mutant proteins had 
comparable half-lives to the A572V mutant protein. It is possible that activation 
induces an allosteric change that makes JAK3 more stable.  This allosteric 
change increases the ability of JAK3 to interact with structural proteins such as 
villin in the cytosol or γc at the membrane, which would explain why the activated 
JAK3 E183G is sequestered away from the nucleus of BaF3 cells.  A detailed 
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crystal structure of the JAK3 FERM with its kinase domain would provide 
significant insight into this mechanism. Our results also raise the possibility of 
FERM domain mutations in other JAK kinases implicated in cancer.  
JAK3 degradation has been previously described as being proteasomally 
regulated. Here, it was found that WT JAK3 degradation may be regulated by 
both the proteasome and the lysosome, whereas activated JAK3 may only be 
regulated by the proteasome.  
The structural model of the JAK3 FERM domain shows that the three 
mutations will disrupt direct interaction with the kinase domain and may play a 
key role in tumor progression. These data suggest that these mutations increase 
JAK3 kinase activity in vitro.  
These results implicate the JAK3 activation as an important therapeutic 
target in ATLL. JAK3 activity can be inhibited with the JAK3 specific inhibitor, 
tofacitinib. A mouse model could be used to probe the effects of JAK3 mutants 
and treatment with kinase specific inhibitors in vivo. Thus far, a human ATLL cell 
line with a gain of function JAK3 mutation has yet to be established, which would 
allow for testing of oncogene dependence directly. It should be noted that growth 
of both Hut-102 and MT-2 cell lines as well as primary ATLL cells, all of which 
are lacking in JAK3 mutations, had phosphorylated JAK3 and were inhibited by 
tofacitinib. This result suggests that there could be oncogene dependence on 
JAK3 even without a gain of function mutation. For example, the Hut-102 cell line 
requires exogenous hIL-2 for optimal growth. The MT-2 cells also have 
deregulation of the JAK3/γc axis in the form of HTLV-1 integration 5’ of the IL9R 
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gene. This retroviral insertion induces overexpression of the receptor such that 
high levels of IL-9R may signal through JAK3 without ligand249, 250. In the 36 
patient samples we analyzed, only a small percentage had activating mutations 
in JAK3. Another study looked at 24 patients and did not find any mutations at all. 
This would imply that other components of JAK3 signaling may be mutated in 
ATLL or othat ther mechanisms could misregulate the pathway since this 
pathway is upregulated in nearly all ATLL samples251.  
Further work needs to be done to identify the exact mechanism of FERM 
regulated kinase activity in JAK3. The most useful study would be to crystallize 
the entire JAK3 protein with and without mutations and directly identify how the 
structure is altered. Alternatively, a series of alanine substitutions in the FERM 
subdomain where the three mutations were identified could identify novel 
regulatory site(s) in both kinase regulation and interprotein interactions. These 
could be used in both the HEK 293T IL-2R recapitulation and the BaF3 
experiments. Also, the C-terminal region of JAK3 containing the entire FERM 
domain was cloned into a GST fusion vector pGEX-2T for wildtype JAK3 and 
each of the ATLL derived JAK3 FERM domain mutations. These fusion 
constructs could be used in vitro kinase and GST pulldown experiments to 
quantifiably measure receptor interaction and the effects of mutations on kinase 
activity in vitro. 
The three activating JAK3 mutations identified in ATLL are weakly 
oncogenic and required the loss of Cdkn2a gene expression to realize its 
potential.  These mice developed tumor much more rapidly than did Cdkn2aKO 
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mice with WT JAK3. That mice developed tumors characteristic of Cdkn2aKO 
mice may be the result of using Cdkn2aKO BM for the donor cell origin and results 
could vary in a model that is not primed for B cell tumors. Alternatively, HTLV-1 
preferentially infects CD4+ T cells and though JAK3 mutations aid in the 
development of ATLL the T cell phenotype, this could reflect the original cell 
phenotype at infection. One way to test this would be in a model in which the 
activation of JAK3 occurs first with subsequent loss of tumor suppressors. As we 
were unable to show that activating mutations in JAK3 are oncogenic alone in a 
BMTT experiment, it may be preferable to use a transgenic mouse model to fully 
understand how activated JAK3 may lead to tumor development. ATLL derived 
JAK3 mutants were cloned from the JAK3-MIG constructs into an expression 
construct under the control of the vav proximal promoter. These constructs could 
be used to make T cell specific JAK3 transgenic mouse lines with activated JAK3 
mutations. Alternatively, we could cotransduce WT C57/B6 BM with both Jak3 
and the oncogene tax. These mice may preferentially develop T cell leukemias.  
JAK3-specific inhibitors were clinically tested in phase I and phase II 
studies of rheumatoid arthritis and may be worth testing in ATLL patients240. The 
three JAK3 FERM domain mutations were shown to disrupt autoregulation of 
JAK3 kinase activity inducing JAK3 to be constitutively active and are oncogenic. 
ATLL is a remarkable example of retrovirally-induced cancer in humans. 
In summary, in the research presented here, three mutations in the FERM 
domain of JAK3 were identified in four of the thirty-six ATLL patients and were 
absent in twenty-three ethnically matched controls that were screened. These 
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somatic, missense mutations occurred in the amino terminal regulatory FERM 
domain.  
All three mutations were found to induce gain of function in JAK3, implying 
an autoregulatory role normally for the FERM domain on JAK3’s kinase. One 
mutation E183G, was further explored in vivo and was found to be weakly 
oncogenic with the additional loss of tumor suppressor proteins p19(ARF) and 
p16(INK4A) in a BMTT model.  These mutant JAK3s can be inhibited with a 
specific kinase inhibitor, tofacitinib, as well as inhibitors against downstream 
activation targets. These findings emphasize the importance of JAK3 activation in 
ATLL development and offer a novel therapeutic target for this otherwise 
incurable disease. 
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